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Abstracts of paperst
Breast cancer
Prognostic value of cellular DNA content in the management
of ductal carcinoma in situ of the female breast
R. Carpenter, J. Matthews, N. Gibbs, B. Thomas, P. Boulter
& T. Cooke
Charing Cross Hospital, Royal Surrey County Hospital,
Guildford Breast Screening Centre and Liverpool Royal
Infirmary, UK.
A prognostic index for ductal carcinoma in situ (DCIS) of
the female breast would allow a rational approach to
management by selecting only the more aggressive lesions for
radical local surgery. We have assessed cellular DNA content
(ploidy) in screen detected, disaggregated DCIS by
integrating microdensitometry after Feulgen staining in an
attempt to identify phenotypically aggressive lesions.
Ploidy of DCIS (n =26) associated with microinvasive
carcinoma was compared with 12 cases of DCIS alone. Only
4 of 12 DCIS lesions was aneuploid compared with 23 of 26
DCIS lesions associated with microinvasive cancer
(P<0.001, x2=9.599). In the screening programme to date
at Guildford, there have been 5 local recurrences in 23 of 40
DCIS lesions treated by excision biopsy, all of the recurrent
cases were originally aneuploid compared with only 6 of 18
cases not associated with recurrence (P<0.05, X2=4.544).
Aneuploidy is a frequent finding in DCIS which has
progressed to the stage of micro invasion and has correctly
predicted recurrence in women who have been treated by
excision biopsy. Aneuploidy is of prognostic value and may
allow selective management in DCIS of the female breast.
Breast duct carcinoma in situ: Clinical data relating to its
sensitivity
P. Price1, A. McKinna2, G. Walsh2, B. Gusterson3 &
J.R. Yarnold'
Departments of 'Radiotherapy, 2Surgery, 3Pathology, Royal
Marsden Hospital and Institute of Cancer Research, London,
UK.
Radiotherapy after lumpectomy in women with early stage
breast cancer reduces the local recurrence rate from >30%
at 5 years to < 10%. The rationale of radiotherapy to the
whole breast includes eradication of multifocal areas of duct
carcinoma in situ (DCIS). However, the radiosensitivity of
DCIS is unknown. A retrospective analysis has been
performed in patients who have breast recurrence after
lumpectomy+radiotherapy for early stage breast cancer. The
incidence of DCIS in relapsed patients has been investigated
in terms of initial primary histology and whether radio-
therapy had been given. Biopsy specimens have been
independently reviewed from patients who relapsed in the
breast after local excision for 10 invasive breast cancer (10
cases), 1° invasive breast cancer with DCIS (26 cases) and
pure DCIS (7 cases). All patients had been treated by
complete LE (1 cm clearance) and RT was given to the
whole breast (usually=60Gy/30F/6 weeks).
DCIS was present in the recurrent tumour in more than
one third of patients, regardless of whether radiotherapy had
been given or not. On analysis, position, timing and
pathology of the recurrent tumour suggests failure to
eradicate original DCIS. These data suggest that high dose
radiotherapy is relatively ineffective in eradicating DCIS in
the vicinity of primary breast cancers and presumably
elsewhere in the breast. These data question the use of
radiotherapy to the whole breast after wide local excision for
invasive breast cancer in the management of patients with
pure DCIS treated by lumpectomy.
A randomised cross-over trial of megestrol acetate vs.
tamoxifen as initial treatment for post-menopausal women with
advanced breast cancer
N. Stuart', C. Tyrell2, D. Spooner1, C. Keen3, A. Taylor4,
J. Tarrant4, G. Blackledgel, D. Webster' & G. Rees6
1Queen Elizabeth Hospital, Birmingham, 2Plymouth General
Hospital, 3Velindre Hospital, Cardif 4Stoke Mandeville
Hospital, Aylesbury, University Hospital of Wales, 6Royal
United Hospital, Bath, UK.
Ninety-six peri- or post-menopausal patients (pts) have been
entered into a randomised, cross-over trial comparing
tamoxifen and megestrol acetate as first-line hormone
treatment (HT) in advanced breast cancer. Interim results
are presented without treatment codes being broken. No pt
had received previous chemotherapy. All pts had disease
measurable or evaluable for response. Median age was 64
(43-89). Forty-six of 88 pts on whom data is available
presented with advanced disease and received study HT as
primary treatment, 42/88 received study HT having relapsed
a median of 48 months after primary treatment. Sites of
dominant disease were: primary tumour, 37 pts; local
recurrence, 6; nodal disease, 8; lung metastases, 11; bone
metastases, 19; skin, 4; other, 2; no data (ND), 9.
Group A comprises 47 pts but 2 of these did not receive
treatment. Thirty-two pts are evaluable for response, 1 (3%)
achieved CR, 3 (9%) achieved PR, 16 (50%) had static
disease for more than 3 months (SD) while in 12 (38%)
disease progressed within 3 months (PD). Nineteen pts have
completed treatment A and of these 14 have crossed over.
Following cross-over 9 are evaluable for response: 6/9 PD,
3/9 SD. Group B comprises 45 pts but 2 of these did not
receive treatment. Thirty-four pts are evaluable for response.
*Enquiries to the BOA Secretariat: J. Tobias, Department of
Radiotherapy, University College Hospital, London WC1E 6AU.
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3 (9%) achieved CR, 13 (38%) PR, 10 (29%) SD and 8
(24%) PD. Ten pts have completed treatment B and of these
8 have crossed-over. Following cross-over 6 are evaluable: 1
PR, 3 SD and 1 had PD. Toxicity has occurred in only a
minority of pts in both groups. In group A 5/34 pts with
follow-up data experienced toxicity during first treatment
(fluid retention=2 pts, glycosuria=3 pts). In group B 6/34
pts experienced toxicity during first treatment (PV
bleeding=lpt, flushes=3 pts, nausea=2 pts). In all cases
toxicity was mild (WHO grade 2 or less).
Interim analysis indicates that both treatments show
broadly comparable response rates in post-menopausal
women with advanced breast cancer. Both produce minimal
toxicity. This study will continue until 200 pts have been
randomised. Final end-points will include initial and cross-
over response rates, toxicity, time to progression and
survival.
Affecting the natural history ofbreast cancer
J.R. Harris & Samuel Hellman2
1Joint Centerfor Radiation Therapy, Harvard Medical
School, Boston and 2Memorial Sloan-Kettering Cancer
Center, New York, USA.
The many changes in breast cancer management offer an
opportunity to review the hypotheses on which these are
based and the evidence that such treatments affect ultimate
survival. Traditional treatment has been based on the notion
that the disease, in many patients, is an orderly one starting
with local disease and then spreading to the regional lymph
nodes and finally distantly. The alternative hypothesis is that
if the disease is to demonstrate metastatic potential, it
metastasizes before clinical presentation and thus local and
regional treatment are of little or no value. Current evidence
seems to argue against the latter hypothesis being regularly
the case since breast cancer mortality can be reduced by as
much as 30% using mammographic screening. Local control
appears to influence the proportion of distant metastases
seen in randomized control clinical trials. Even in patients
with positive nodes improved local control is associated with
improved survival. Systemic therapies are also available for
the treatment of occult distant metastases. While evaluation
is limited by the restricted follow-up time, it is clear that
survival curves are altered and that survival is prolonged.
What is not clear is whether the proportion of patients cured
of the disease has changed.
Radiation induced brachial plexus damage and time-dose
fractionation - A clinical and CT study
S. Powell, J. Cooke & C. Parsons
Royal Marsden Hospital, London, UK.
The radiation tolerance of the brachial plexus was
investigated in 459 patients with breast cancer treated post-
operatively. The effects of two radiation schedules were
compared: 60Gy in 30 fractions or'51 Gy in 15 fractions,
both over 6 weeks. Patient follow-up was 30-58 months after
radiotherapy. The incidence of neurological damage to the
brachial plexus was 2.7% with large fraction size (3.4Gy)
and <1% with small fraction size (2Gy).
Computed tomography (CT) of the root of neck and
axilla, using bolus i.v. contrast to improve visualisation of
the brachial plexus, was performed in 42 patients (44 CT
scans). A pattern of increased soft-tissue density (ISD)
surrounding the brachial plexus was interpreted as a post
radiation effect, distinguishable from recurrent disease.
Ninety-six per cent (27/28) of patients with a clinically
detectable brachial plexus lesion had ISD, while only 50%
(8/16) of patients with no neurological deficit had ISD. The
pattern of ISD was not related to nodal disease status, type
of axillary surgery or technique of radiotherapy. The degree
of ISD (graded mild, moderate or severe) appears to be
associated with large fraction size. Fifty-four per cent (17/31)
of patients receiving large dose per fraction had moderate or
severe ISD, compared with 23% (3/13) of patients treated
with small dose per fraction.
It is concluded that CT can usefully assess the degree of
post radiation effect, and that the radiation tolerance of the
brachial plexus is largely dependent on fraction size. The
relationship between total dose and fraction size can be
calculated.
Elucidating the action of the antioestrogens? Response to
toremifene (Fc-1157a) therapy in tamoxifen failed patients
S.R. Ebbs, J.V. Roberts, A.J. Wilson & M. Baum
Department ofSurgery, Kings College Hospital, London, UK.
The clinical activity of the triphenylethylene group of drugs
does not demonstrate an absolute correlation with their anti-
oestrogenic activity or the oestrogen receptor content of the
tumour.
Toremifene (Fc-1157a) is a new triphenylethylene anti-
oestrogen which at low concentrations produces effects
comparable with tamoxifen. At higher dose toremifene exerts
anti-tumour effects, some of which are different from those
of tamoxifen and are directed against oestrogen receptor
negative breast tumours and tumours ofmesenchymal origin.
The exact mechanism of these effects is unknown.
To determine whether this effect seen in experimental cell
lines and animal models is reproducible in man we have used
toremifene as a second line therapy in patients who have
relapsed whilst receiving tamoxifen.
In 9 patients treated for over 3 months toremifene
produced a partial response in 3, (33%) and no change in 3,
(33%) using UICC criteria.
A single patient with multiple desmoid tumours who
relapsed after responding to tamoxifen also responded
dramatically to toremifene.
As this is a group of patients who had relapsed whilst
receiving tamoxifen, it may be that, as in cell culture and
animal experiments, we are witnessing an alternative
pathway of action perhaps mediated by effects on
mesenchymal cells.
Conference Lecture
Early breast cancer trialists collaboration
R. Peto
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK.
Taken in isolation, most clinical trials in early breast cancer
would not be capable of determining reliably whether a
particular adjuvant treatment had (a) no material effect on
survival, or (b) a moderate yet humanly worthwhile effect
(e.g. reducing 5-year mortality from 1/3 down to 1/4). An
overview of all available randomised trials might, however,
be accurate enough for this purpose, and a large number of
trialists have therefore chosen to collaborate in such an
overview. Some of the main results from this collaboration
will be presented on their behalf. Among women aged over
50, 2 years of tamoxifen reduced 5-year mortality from 33%
to 25%, an effect that was overwhelmingly statistically
significant. Among women under 50, however, the number
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evidence of an effect of tamoxifen on mortality existed,
either because it has little effect on mortality or because the
results were distorted by the play of chance. For
polychemotherapy, the opposite pattern was apparent: it
produced a highly significant mortality reduction among
women under the age of 50, but a smaller and less clearly
significant effect among older women. For both agents, the
proportional changes in outcome appeared similar for women
with no, few or many axillary nodes. The effects on long-
term survival after 5 years are not yet known.
Lung cancer
Radiotherapy employing 3 fractions each day over a
continuous period of 12 days
M.I. Saunders & S. Dische
Marie Curie Research Wing, Mount Vernon Hospital,
Northwood, Middlesex, UK.
Studies in the cell kinetics of human tumours have given
support to the use of accelerated fractionation to overcome
regrowth of tumours between fractions. Any pause in
treatment as may occur with a split-course schedule, or even
for the week-end, is likely to negate the benefit to be
obtained. We have administered 36 treatments over a
continuous period of 12 days with a 6 hour gap between
each of the three treatments given each day. Seventy-four
patients with intra-thoracic and head and neck tumours have
now been included in this study. Acute reactions have been
tolerable and it was found possible to increase the minimum
tumour dose from a total of 50.4 to 54.0Gy. Immediate
tumour responses have been promising. Twelve (46%) of 26
assessable patients with carcinoma of the bronchus have
shown complete radiological regression and this can be
compared with 9 (16%) of 62 similar patients included in a
previous study. Twenty-one patients with advanced head and
neck tumours have shown a rapid response in the primary
site with complete regression and healing occurring in all
except one case. The method has proved to be a practical
one and the promising tumour responses, together with the
expectation of a low incidence of late changes, encourages
further exploration of this regime.
Feasibility study of alternating radio-chemotherapy using
multiple fractions per day in patients with small cell lung
cancer (SCLC)
D. Parton', J.R. Yarnold' & I.E. Smith2
Departments of'Radiotherapy and 2Medicine, Royal Marsden
Hospital, Surrey, UK.
Alternating courses of cytotoxic chemotherapy and hyper-
fractionated radiotherapy may improve the therapeutic ratio
in LDSCLC. Fourteen patients were entered in to a
feasibility study of hyperfractionated radiotherapy
intercalated between courses of induction chemotherapy.
WHO performance status at presentation was 0 or 1 in all
patients. Median age at presentation was 61 years, range 50-
69. Five courses of JM8 (400mgm 2 day 1), Ifosfamide
(5gm-1 day 1), VP16 (lOOmgm-2 days 1-3) were given at
28 day intervals. Five days after the first and second courses
of chemotherapy a 5 day course of radiotherapy was given
to the primary tumour and mediastinum by AP opposed
fields using 5 Mev X-rays. Each course of radiotherapy
delivered 15Gy tumour dose in 15 fractions over 5
consecutive days with a 3h gap between fractions. During
the period of intercalated radio-chemotherapy, performance
status remained unchanged or improved in 9/14 patients and
deteriorated in 5 patients including 1 death. Six of 27 (22%)
courses of radiotherapy were associated with oesophagitis
(all WHO grade III); onset was the sixth day after start of
radiotherapy with resolution within 8 days. Eight of 14
patients have been followed up for a minimum of 2 months
following completion of radiotherapy and 4 have radio-
logical pneumonitis (1/4 has clinical pneumonitis). In
conclusion, the incidence and severity of oesophagitis and
pneumonitis are higher than expected and may reflect
enhancement by high dose cytotoxic agents, especially
ifosfamide. Tumour response rates are high and the protocol
continues but with limited scope for escalating the radiation
dose.
Chemotherapy for cerebral metastases in small cell carcinoma
of the lung (SCCL)
C.J. Twelves', J.S. Tobias2, P.G. Harper', C.M. Ash2,
B. Mantell3, R.L. Souhami2, S.G. Spiro4 & D.M. Geddess
'Guy's, 2University College Hospital, 3The London Hospital,
4Brompton Hospital, 5London Chest Hospital, London, UK.
Within a chemotherapy trial for SCCL, patients with
cerebral metastases were identified as a special sub-group. By
withholding cranial irradiation the aim was to evaluate the
effect of chemotherapy as initial treatment for cerebral
metastases. Responses were objectively assessed by a series of
CT brain scans.
Twenty-five patients (4.1%) had CT proven cerebral
metastases at presentation, but 5 underwent cranial
irradiation, and 2 craniotomy prior to chemotherapy. The
remaining 18 patients were treated with cyclophosphamide
1 gm-2 i.v. day 1, vincristine 2mg i.v. day 1 and etoposide
100mg t.d.s. p.o. days 1-3, q3w. Steroids were given where
clinically indicated at the lowest possible dose.
Nine of 14 patients who had a repeat CT scan achieved a
CR or PR. One of the 4 clinically assessable patients also
improved, giving an overall response rate of 54%.
Radiological responses were rapid, sustained, accompanied
by clinical improvement and included 7 patients who had
not received steroids.
Chemotherapy has previously been discounted as
treatment for cranial metastases because of the assumption
that the blood brain barrier (BBB) protects them from
systemic chemotherapy. In fact metastases develop their own
tumour circulation which probably has no BBB. In SCCL
cerebral metastases respond to chemotherapy which may be
considered for first-line palliative treatment, having several
advantages over radiotherapy.
Treatment duration in small cell lung cancer (SCLC). A
randomised comparison of 4 versus 8 courses of initial
chemotherapy
J.S. Tobias', R.L. Souhamil, C.M. Ash', S.G. Spiro2,
D.M. Geddes3, P.G. Harper4, H.M. Earl' & H. Quinn'
' University College Hospital, 2Brompton Hospital, 3London
Chest Hospital and 4Guy's Hospital, London, UK.
Six hundred and sixteen patients with SCLC were entered
into a randomised trial comparing different treatment
durations and the value of chemotherapy on relapse. Patients
were staged by isotope bone scan and liver ultrasound, and
stratified according to stage (limited or extensive). Patients
were then randomised to receive either 4 or 8 courses of
chemotherapy (cyclophosphamide I gm-2 day 1, vincristine
2mg day 1, etoposide 100mg t.d.s. days 1-3) 3 weekly. At
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relapse, either to receive further chemotherapy (doxorubicin
50mgm 2, and methotrexate 50mgm-2, every 3 weeks) or
symptomatic treatment alone.
Response rates to short (S) and long (L) initial chemo-
therapy were similar (S=61%, L=63%), as were response
rates to relapse chemotherapy (S=25%, L=18%). Overall
median survival (MS) from course one was analysed by
intention to treat, and patients randomised to 8 courses of
initial chemotherapy had a slightly longer MS than those
randomised to 4 courses (MS, 39 vs. 32 weeks, P=0.085).
Progression free interval (PFI) after initial chemotherapy was
longer in patients receiving 8 rather than 4 courses (Median,
31 vs. 23 weeks, P=0.0002). Survival from relapse was
longer for patients receiving relapse chemotherapy than for
those receiving symptomatic treatment alone (MS, 17 vs. 12
weeks, P=0.0004). Patients who received short course
chemotherapy, and no further chemotherapy at relapse,
clearly survived for a significantly shorter time than the
other three treatment groups.
Long-term follow-up of 72 patients given prophylactic cranial
irradiation for small-cell lung cancer
J.R. Johnson & D.A.L. Morgan
Hogarth Centre ofRadiotherapy and Oncology, Nottingham,
UK.
The role of prophylactic cranial irradiation (PCI) in the
combined-modality management of small-cell lung cancer
(SCLC) remains unsettled. We have analysed the long-term
results of such treatment as employed in a standard fashion
at a single institution over a 5-year period.
From 1978 to 1983, 72 patients with SCLC received PCI,
of whom 58 had limited disease and the irradiation was part
of induction treatment; 14 had extensive disease and were
treated after showing a good response to chemotherapy.
The technique employed utilised opposed portals, with no
compensators, delivering a mid-plane dose of 30Gy in 10
fractions from either a Cobalt-60 Unit or a 6MV linear
accelerator. A standard chemotherapy regimen comprising
vincristine, adriamycin and cyclophosphamide was used.
Fourteen of the patients subsequently developed brain
metastases, 2 developed severe non-metastatic neurological
impairment, and 4 died of neurological disease of uncertain
aetiology (CT scanning was not available in Nottingham at
that time). Three patients are alive, well and disease-free.
PCI entails considerable morbidity, and is of unproven
value: its use should be restricted to prospective evaluation
in controlled clinical trials.
The dose-rate effect and recovery in human tumour cells
G.G. Steel, J.M. Deacon, G.M. Duchesne, A. Horwich,
L.R. Kelland & J.H. Peacock
Radiotherapy Research Unit, Institute ofCancer Research,
Sutton, Surrey, UK.
The radiation response of 12 cell lines derived from a variety
of human tumours has been investigated over the dose-rate
range from 150 to 1.6cGymin-1. As the dose-rate was
lowered, the amount of sparing varied widely; in two cell
lines it was zero, in the other cell lines the dose required for
10-2 survival ranged up to twice the value at high dose-rate.
Low dose-rate irradiation discriminates better than high
dose-rate between tumour cell lines of differing
radiosensitivity. The data are equally well fitted by two
mathematical models of the dose-rate effect: the LPL model
of Curtis and the Incomplete Repair model of Thames.
Analysis by the LPL model leads to the conclusion that the
theoretical radiosensitivity in the total absence of repair was
rather similar among the 7 cell lines on which this analysis
was possible. What differs among these cell lines is the
extent of repair and/or the probability of direct infliction of
a non-repairable lesion. Recovery from radiation damage
was also examined by split-dose experiments in a total of 17
human tumour cell lines. Half-time values ranged from 0.36
to 2.3h and there was a systematic tendency for split-dose
halving times to be longer than those derived from analysis
of the dose-rate effect. This could imply that cellular
recovery is a two-component process, low-dose rate sparing
being dominated by the faster component.
Lymphomas and leukaemia
Stage III Hodgkin's disease - Long term results
M. Brada, J. Nicholls, S. Ashley, M. Coleman,
M.J. Peckham & A. Horwich
Institute ofCancer Research and Royal Marsden Hospital,
Sutton, Surrey, UK.
We performed a retrospective analysis of 215 patients with
clinical (CS) and pathological Stage (PS) III Hodgkin's
disease (HD) treated at the Royal Marsden Hospital between
1963 and 1985 (median follow-up of patients alive - 9 years;
range 1-21 years). Eighty-four patients had PSIII (initial CSI
& II) and 131 patients CSIII (53 laparotomised)
histologically confirmed HD. All had infra-diaphragmatic
assessment by lymphography and/or CT scan. The following
prognostic factors were analysed: age, sex, histology,
presenting level of haemoglobin and ESR, systemic
symptoms, sites, extent and bulk of disease. In addition we
assessed the influence of initial treatment modality.
The actuarial 5 and 10 year survival was 77% and 65%
respectively, with 56% and 49% 5 and 10 year disease-free
survival. Although many factors affected the disease-free
survival, the only major prognostic indicator for survival was
age.
Ninety-one patients were initially treated with combined
chemotherapy and radiotherapy (CMT). Their survival was
significantly better when compared to patients treated with
radiotherapy (73 patients) or chemotherapy (51 patients)
alone. When corrected for age, patients under 40 years
treated with CMT demonstrated an improved survival, but
this did not reach statistical significance. The role for CMT
in Stage III HD should be tested in a prospective
randomized trial.
Bone marrow transplantation in lymphoblastic lymphoma in
remission - Autologous versus allogenic
J.G. Gribben, A.H. Goldstone, L. Dones & P. Ernst
The EBMTLymphoma Group.
Seventy-four patients with lymphoblastic lymphoma have
been treated by bone marrow transplantation in complete
remission of disease, 27 by allogenic transplant and 47 by
autograft. All of the allografted patients were conditioned
using a total body irradiation (TBI) containing regimen, but
TBI was used in only 13/47 in the autograft group.
At the time of analysis 49 patients were alive, 18/27 (67%)
in the allograft group and 31/47 (66%) in the autograft
group. Six patients died during the procedure, 3 (11%) of
the allografts and 3 (6%) in the autograft group. Nine (33%)
of those allografted developed GVHD assessed as Grade II
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Relapse of disease was the principal cause of death in both
groups. Patients transplanted in first CR had a disease free
survival advantage over those transplanted in subsequent
CR.
The source of marrow, whether autologous or allogenic,
was found not to influence overall survival or probability of
relapse.
Central nervous system involvement in patients receiving
autologous bone marrow transplantation for non-Hodgkin's
lymphoma
J.G. Gribben, A.H. Goldstone, L. Dones
Department ofHaematology, University College Hospital,
London, UK.
Of 309 patients reported to the European Bone Marrow
Transplant Group (EBMT) with non-Hodgkin's lymphoma
who have been treated by autologous bone marrow
transplantation (ABMT), 24 (7.8%) had CNS involvement.
There were 21 males and 3 females. Twelve were children
aged less than 15 years and 12 were aged 16-58 (median 43)
years. Three had intermediate grade histology, 6 had high
grade lymphoblastic, 6 had other high grade and 11 had
Burkitt's lymphoma.
Fourteen had CNS involvement at the time of diagnosis
and of these 3 still had CNS involvement at the time of
ABMT. Ten further patients had CNS involvement at
relapse so that 13 patients had CNS disease at the time of
ABMT.
Fifteen of 24 (62.5%) achieved or maintained complete
remission (CR) post ABMT. Of these, 9 patients were in CR
at the time of ABMT and 2 (22%) have subsequently had
CNS relapse. The remaining 7 patients remain alive and
disease-free at 3-28 months post ABMT. Of 13 patients who
had CNS involvement at the time of ABMT only 4 (30%)
remain alive at 23-68 months post ABMT.
The overall survival of the 24 patients is not different from
that of the total NHL group (P=0.67). Those patients who
had CNS disease at the time of ABMT have poor survival.
The effect of immunohistological diagnosis on the clinical
management and prognosis of malignant tumours of uncertain
origin
M.H. Robinson', C.J. Alcock2 & D.Y. Mason3
'Royal Marsden Hospital, London, 2Churchill Hospital,
Oxford, and 3John Radcliffe Hospital, Oxford, UK.
The value of a panel of monoclonal antibodies in clarifying
the diagnosis of tumours of uncertain origin has been
established. A retrospective study of the effect on
management and prognosis of 82 patients referred for this
clarification has been performed The original diagnosis was
changed to non-Hodgkins lymphoma (NHL) in 28 cases
labelled carcinoma, 1 labelled germ cell tumour and 1
Hodgkins disease; and to melanoma in 3. Three diagnosed as
NHL became carcinoma. Mean age of patients was the same
in carcinoma and lymphoma groups - 62 years. Mean
follow-up for lymphomas was 25.6 months, carcinomas 19
months, others 17.9 months. Sites of disease were mainly in
lymph nodes, thyroid, skin, gut and bone. Management was
changed in 25/28 patients whose diagnosis became NHL
from carcinoma, 2/3 of those changed from NHL to
carcinoma and in the 3 changed to melanoma. Surgery was
either modified or abandoned in 6 cases and chemotherapy
added or modified in 14. Seven patients rediagnosed as high
grade NHL received aggressive chemotherapy. The doses of
radiotherapy given were reduced in 13/32 and increased in
3/32 patients as a result of change of diagnosis. The response
to treatment in the originally and newly diagnosed NHL
groups respectively were CR 60% and 54%; PR 20% and
17%; PD 20% and 23%. The responses in the carcinoma
and other tumour groups were similar with CR-35%, PR-
41%, SD-6%, and PD-18%. However median survival in
these patients was only 15 months compared to 24 months
for the lymphoma group as a whole (logrank P<0.05). This
panel of monoclonal antibodies provides a clinically useful
investigation upon which to base the treatment and predict
the prognosis of patients with tumours of uncertain
histological type.
Conference lecture
Alpha transforming growth factors in normal and malignant
human mammary epithelial cells
D.S. Salomon, S. Bates, R. Dickson, N. Kim, E. Valverius,
M. Lippman & W.R. Kidwell
Laboratory of Tumour Immunology and Biology and Medicine
Branch, National Cancer Institute, National Institutes of
Health, Bethesda, Maryland, 20892, USA.
Transforming growth factor alpha (TGFa) has been
circumstantially implicated in the autocrine-stimulated
growth of a number of rodent and human tumour cells. In
addition, the enhanced expression of several oncogenes, such
as ras, can increase the synthesis and secretion of TGFa
whereas increased expression of the myc oncogene can
hypersensitize cells to the biological effects of TGFa and
epidermal growth factor (EGF). TGFa functionally and
structurally resembles EGF since it is able to compete with
EGF for binding to EGF receptors and since it is capable of
stimulating the anchorage-independent growth (AIG) of
nontransformed cells, such as NRK cells, in soft agar.
Because overexpression of the Harvey (Ha)-ras and myc
oncogenes occurs in a subset of human breast cancers, the
role that TGFax might perform in these tumours assumes
increased importance. Moreover, TGFa may function as a
proximal effector for certain mammotrophic hormones such
as oestrogen E2. Conditioned medium (CM) from several
human breast cancer cell lines, including MCF-7, T47, ZR-
75-1, and MDA-MB-231, contains a high molecular weight
(30kDa) TGFa activity that can compete with EGF in an
EGF radioreceptor assay (RRA), which can stimulate the
AIG of NRK cells in soft agar and which can react with
monospecific TGFx antibodies in a competitive radio-
immunoassay (RIA) or following radioimmunoprecipitation.
The CM levels of immunoreactive TGFax range from 0.5 to
40ng 10-8 cells, woth the MDA-MB-231 cells exhibiting the
highest levels and ZR-75-1 cells possessing the lowest levels.
Treatment of oestrogen-responsive MCF-7, T47-D, and ZR-
75-1 cells with E2 (10-8M) produces a 2- to 5-fold increase
in the CM levels of biologically active and immunoreactive
TGFa. Following Northern blot analysis with a human
TGFac cDNA probe, a specific 4.8-kb TGF mRNA species
can be detected in the poly (A)+ RNA isolated from the
human breast cancer cell lines at levels proportional to the
amounts of secreted TGFa in the CM. Treatment of MCF-7
cells with E2 in vitro for 6h leads to a 2- to 3-fold induction
in the level of TGFa mRNA expression. Furthermore,
withdrawal of oestrogen from nude mice bearing oestrogen-
dependent MCF-7 tumours results in a decrease in TGFax
mRNA levels within 2 to 3 days. Polyclonal antibodies
against human TGFai can inhibit the AIG of MCF-7 cells in
soft agar. Transfection of a v-Ha-ras oncogene into MCF-7
cells abrogates the in vitro and in vivo growth-promoting
effects of E2 and augments the production of TGFcx by 3- to
4-fold with a loss of E2 induction. TGFoa protein and
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human breast tumours. TGFa is not restricted to malignant
human mammary epithelial cells. For example, primary
cultures of normal human mammary epithelial cells (HME)
or HME cells that have been immortalized with benzo-a-
pyrene (AIN4) contain biologically and immunologically
active TGFa in their CM and express a 4.8-kb TGFa
mRNA. Following Southern blot analysis, no evidence for
amplification or gross rearrangements of the TGFa gene was
observed in any of the breast cancer cell lines or in the
A1N4 cells. These results, in conjunction with the
observation that comparable TGFa species have been
identified and purified from human milk, suggest that TGFa
is functioning as a mitogen for normal proliferating and
neoplastic human mammary epithelial cells.
Gynaecological cancer
Radiobiology of human squamous cell carcinoma of the cervix
L.R. Kelland, K.S. Tonkin, L. Burgess & G.G. Steel
Institute ofCancer Research, Sutton, Surrey, UK.
The clinical management of carcinoma of the cervix consists
primarily of surgery and radiotherapy employing both
external beam high dose-rate and intracavitary low dose-rate
regimes. From human cervix carcinoma biopsies we have
established four new continuous cell lines which, in addition,
are serially transplantable as xenografts in nude mice. We
are using these to investigate the in vitro and in vivo
radiobiological properties of this disease.
In vitro studies have been performed using single cell
suspensions of tumour cells, plated out and irradiated with
60Co A-rays at high dose-rate (150cGymin-1) and
continuous low dose-rates (3.2, 1.6cGymin-1). Cells were
held at 37°C in a 5% C02, 5% 02, 90% N2 atmosphere
throughout irradiation and assayed for survival by in vitro
cloning. For in vivo studies, tumours were grown as
xenografts over the dorsal spine of nude (nu/nu) mice and
the tumours were irradiated at dose-rates of 75 and
5cGymin-1 with lead shielding of the body. The end-point
used was tumour growth delay.
Results showed that both in vitro and in vivo, variations in
acute survival parameters and wide variations in low dose-
rate sparing occurred between the lines. The most
radioresistant line HX156 showed substantial dose-sparing in
vitro (Dose Reduction Factor of 1.51 at the 1% survival
level for 150 versus 1.6cGymin-1) whereas for HX151 this
was only 1.14. The large amount of sparing in HX156 was
also reflected in vivo with tumour growth delays of 4.0 and
1.1 for 12Gy total dose administration at dose-rates or 75 or
5cGyminm ' respectively.
Neo-adjuvant bleomycin, methotrexate and CCNU in advanced
radically inoperable squamous cell carcinoma of the vulva
K.R. Durrant, C. Mangioni, M. George, A. La Cave,
M.E.L. Vandeburgh, N. Rotmenz & J.B. Vermorken
EORTC Gynaecological Cancer Cooperative Group, Churchill
Hospital, Oxford, UK.
Radical vulvectomy is the treatment of choice for squamous
cell carcinoma of the vulva. Down-staging of inoperable
disease by radiotherapy or chemotherapy is impeded by the
age and poor general condition of these patients.' Therefore
low dose chemotherapy with bleomycin, methotrexate and
CCNU has been studied in 23 patients with radically
inoperable vulval cancer for clinical efficacy, operability after
chemotherapy, and side-effects profile. All had histologically
verified squamous carcinoma, inoperable, measurable, and
not pretreated. Patients with distant metastases or severe
coexistent disease were excluded. Chemotherapy was given in
a 6 week cycle using a complex schedule of dose
modification for toxicity: BLM 5mg i.m. days 1-5, then days
1 and 4 each week, CCNU 40mg p.o. days 5-7, MTX 15mg
p.o. days 1 and 4 each week. A minimum of one cycle was
given and repeated four times or until response.
Eighteen patients were fully evaluable, 11 with primary
tumours, 7 with recurrent disease. The mean age was 75
years, mean performance status was 1.
Response Operability
Complete 2 Not operable 11
Partial 10 Surgery performed 4
No change 4 Not evaluable 1
Progression 2 Too early to assess 2
Side effects were more severe than expected from pilot
studies with frequent stomatitis, nausea and infection.
Advanced and recurrent cervical cancer - Active chemotherapy
G. Constantine', C. Meanwell', G. Blackledgel, J. Mould',
A. Chetiyawardanal, D. Spooner', T. Latiefl, F. Lawton',
J. Kavanagh', J. Tobias2, M. Patterson3, M. Sokal4 & C.
Alcock'
'Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham
B15 2TH; 2University College Hospital, London; 3Northern
General Hospital, Sheffield; and 4General Hospital,
Nottingham; and 5Churchill Hospital, Oxford, UK.
Thirty-five evaluable patients with recurrent or disseminated
cervical cancer were entered into a prospective trial of
bleomycin (30mg infused over 24h), followed by cis-
platinum (50mgm-2 bolus) and ifosfamide (5gm-2 infused
over 24h), with concomitant hydration (total 101 over 3
days) and mesna (8gm 2 given during and for 12h
following ifosfamide). Patients received between 1 and 8
courses (mean=4.3). Twenty-seven of 35 had previously
received radiotherapy (RT).
Twenty-five (72%) objective responses were seen. Seven
women had a CAT span complete response. Most patients
noted a subjective improvement in disease related symptoms.
Seven patients went onto further RT to consolidate the
response. Response duration to date varies between 6 and 35
weeks with chemotherapy alone, 7 patients having a
continuing response. All patients experienced alopecia and
nausea/vomiting. Fifteen (43%) needed one or more blood
transfusions, 6 (14%) developed a septicaemia, 7 (20%)
developed grade 1 or 2 ifosfamide encephalopathy, 2 patients
developed renal damage and there was 1 death from
septicaemia.
Twelve further patients with advanced disease have been
treated in a neo-adjuvant setting prior to RT, 70% having a
>50% reduction in tumour size within 2 courses. These data
indicate that BIP may be used for effective palliation and
debuling in around 70% of patients with advanced or
recurrent cervical cancer. A multi-centre randomised trial has
been launched to determine whether neoadjuvant BIP
improves survival in patients with inoperable cervical cancer.SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 865
Evaluation of toxicity in patients with ovarian carcinoma
treated by intensive combined modality therapy
S. Myint, J.A. Green, R.D. Errington, A.J. Slater &
H.M. Warenius
CRC Department ofRadiation Oncology, University of
Liverpool, UK.
Forty-six high risk patients with ovarian carcinoma were
treated by intensive combined modality therapy. Thirty-three
patients had TAH/BSO completed and after surgery 21
patients had bulky residual disease. All 46 patients received
combination chemotherapy with cis-platinum and cyclophos-
phamide following surgery and 18 patients had complete
abdomino-pelvic radiotherapy. Thirty-eight patients (65%)
were in complete remission including 10 patients who had
pathological CR. Overall response was 78% and 55% of
patients were alive at 30 months.
Toxicity of the intensive combined modality therapy is
reviewed. Data on haematological, GI tract, renal and
hepatic toxicities are presented. In all 18 patients who had
had all 3 treatment modalities, the toxicity was moderate but
tolerable. There were no toxic deaths related to treatment.
Intensive combined modality therapy is necessary in high
risk patients to improve results, both in terms of local
control and survival, but toxicity from such therapy should
be borne in mind.
The assessment of bladder dosage in intracavitary therapy of
carcinoma of cervix
R.D. Hunter1 & H.M. Notley2
Departments of'Radiotherapy and 2Medical Physics, Christie
Hospital and Holt Radium Institute, Manchester M20 9BX,
UK.
Pelvic dosimetry in intracavitary therapy has always been a
problem because of difficulties in identifying easily the
position of individual organs and of expressing dosage to
them in view of the inhomogeneity of the exposure. As a
compromise ICRU 38 defined bladder dosage by reference
to the post wall of a Foley catheter balloon. Previous data
from this hospital demonstrated that there was no
correlation between this ICRU bladder reference dosage and
the maximum dose to the posterior bladder wall in patients
undergoing intracavitary therapy. This study defined a
vertical plane through the upper vaginal applicator in which
the maximum bladder base dosage was likely to occur.
Subsequent studies failed to find any correlation between the
distance from the mid plane of the vaginal ovoids and the
posterior bladder wall and (1) stage, (2) age or (3) size of
vaginal applicators. This distance can be calculated by CT
scanning but this is impractical in routine clinical practice. A
new technique will be described in which the bladder base
and posterior wall can be defined in a patient undergoing
intracavitary therapy using conventional radiography. A
group of 20 patients have been investigated in whom the new
technique has been correlated with CAT scanning. The use
of the new technique on conventional radiographs allows the
bladder to be visualised successfully and helps to explain
many of the problems encountered previously.
Conference lecture
The strategy for new drug development
M.F.G. Stevens
Department ofPharmaceutical Sciences, Aston University,
Birmingham, UK.
Genes coding for proteins which confer multiple drug
resistance and the ability to repair DNA alkylation lesions
provide the cancer cell with the means to subvert
intervention by many antitumour drugs. Similarly,
amplification of genes coding for the protein structures of
vital enzymes (e.g., dihydrofolate reductase or thymidylate
synthetase) provide the cancer cell with the ability to develop
resistance to drugs targeted to these enzymes, and others. A
similar outcome is likely to frustrate the efforts of drug
designers developing new generations of agents targeted to
oncogene protein products (e.g. growth factors and growth
factor receptors).
A new strategy for drug development will focus on the
design of agents which can recognise, in a sequence-specific
manner, key oncogene nucleotide sequences and either
silence the transcription of the gene or inhibit translation of
the messenger RNA sequence. The structures of prototype
molecules in this new class will be discussed and prospects
for success of this strategy reviewed. The Cancer Research
Campaign has established a programme with the resources
to bring novel drug moieties into clinical trial: these new
moieties will be selected on different biological criteria than
hithertofore.
Brain tumours
Growth failure following irradiation in children with brain
tumours
E.A. Livesey, C.G.D. Brook, A.C. Whitton, J.A. Britton,
J.S. Tobias & H.J.G. Bloom
Middlesex, University College and Royal Marsden Hospitals,
London, UK.
We have studied the growth and endocrinology of 120
children from a cohort of 140 who are in clinical remission
following treatment of a brain tumour. All received cranial
irradiation, 66 spinal irradiation and 32 adjuvant
chemotherapy. Mean age at treatment was 6.3 years (0.8-15).
Mean follow-up since completing radiotherapy was 8.5 years
(1.2-26).
Thirty-two had completed their growth before endocrine
assessment. Fourteen who had received spinal irradiation
had a mean final standing height standard deviation score
(SDS) of 1.82 below the mean for the normal population
and mean final sitting height (reflecting spinal growth) SDS
-2.94. Eighteen treated with cranial irradiation alone had a
final height SDS of -0.94 and final sitting height SDS of
-1.21. Hence spinal irradiation has a slightly significant
effect on final height.
Low height velocity, reflecting the rate of growth, was
observed in 94 children followed prospectively, and growth
hormone insufficiency (in response to insulin induced
hypoglycaemia) was found in 83 of 85 children assessed. The
incidence of growth hormone insufficiency is clearly higher
than has previously been reported.
Forty children were treated with growth hormone and all
responded with improved height velocity. Delay in instituting
treatment in growth hormone deficient children leads to an
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irreversible loss of final height prognosis. Prospective follow-
up and early intervention are essential to achieve a normal
final adult height.
The influence of field size on the radiation tolerance of the
spinal cord: Experimental fmdings leading to a reappraisal of
clinical data
A. Morris' & A. Dixon-Brown2
1Research Institute and 2Department ofRadiation Physics,
Churchill Hospital, Oxford OX3 7LJ, UK.
pH in human brain tumours
R.P. Beaney1, D.J. Brooks2, D.G. Thomas2 & I. Silver3
'Queen Elizabeth Hospital, Birmingham; 2National Hospital
for Neurological Diseases, London; and 3Department of
Pathology, University, Bristol, UK.
Current teaching would lead us to believe that most if not all
tumours have a pH lower than that of normal tissue. Studies
using new techniques, e.g., magnetic resonance spectroscopy,
have challenged this belief. We studied regional cerebral pH
using 2 independent techniques. Using positron emission
tomography and continuous inhalation of 11CO2 we
measured regional cerebral pH in 12 patients with intra-
cranial tumours. This technique allowed us to determine the
intracellular pH of both normal and neoplastic brain in a
virtually non-invasive fashion. Regional pH in 8 out of 12
tumours was higher than that of normal brain. Mean
regional tumour pH for the group as a whole (7.03+0.07)
did not differ significantly from that of contralateral cortex
(7.00+0.05). Five patients had pH electrode measurements
during craniotomy, 2 out of 5 patients had a tumour pH
higher than normal brain, though mean regional tumour pH
was not significantly elevated for the group as a whole.
There is now evidence to suggest that not all tumours are at
a pH lower than that of normal tissue. Admittedly the newer
techniques involve mean measurements for a volume of more
than a cubic centimetre. In future rather than assuming all
tumours to be acidic it may be important to establish the pH
of individual tumours or different tumour types. This would
allow specifically tailored treatment to be given that would
exploit any difference in pH to the full.
CT computerised stereotactic multiple biopsies for low density
CT lesions presenting with epilepsy
J.N. Wilden1 & P.J. Kelly2
'Institute ofNeurological Sciences, Southern General
Hospital, Glasgow, UK; and 2Department ofNeurosurgery,
Mayo Clinic, Rochester, USA.
Thirty-five patients presenting with epilepsy alone and a
non-enhancing low density lesion on the CT scan underwent
computer-assisted CT-guided multiple stereotactic biopsies
with stereotactic angiographic control. There was no
mortality or morbidity in this series and the diagnostic yield
was 97%. Thirty-four patients had low grade intra-axial
neoplasms. After an estimation of the pathological extent of
the tumour, 3 patients underwent a computer-assisted
stereotactic laser resection and 28 patients had radiotherapy.
Multiple serial biopsies offer a method of estimating the
pathological boundaries of the tumour in three dimensions.
Once these boundaries are known a more rational decision
can be made regarding the feasibility of the total versus
partial surgical resection of low grade intra-axial neoplasms
and can be helpful in planning radiotherapy.
It is current clinical practice to reduce the total therapy dose
as the length of spinal cord irradiated is increased. The early
clinical findings of Boden (1948) are frequently quoted in
support of this approach, even though his conclusions were
based on very limited data. While several subsequent authors
have made reference to a field size effect, little or no
additional data was presented and precise relationship has
been established.
In a recent series of experiments in the rat, 4, 8 and 16mm
lengths of cervical cord were irradiated. The dose related
incidence of paralysis within <30 weeks (white matter
damage) and for intervals >30 weeks (vascular damage) was
assessed. For paralysis within 30 weeks a field size effect was
seen, the ED50 value increased from 21.5+0.3Gy for a
16mm field to 50.98+2.28Gy for a 4mm field. However,
this effect was largely lost for the later damage; ED50 values
ranged from 20.0+0.5Gy (16mm) to 25.58+2.78Gy
(4mm), moreover at .ED25 no significant field size effect
was observed.
From an analysis of data from a paper by Reinhold et al.
(1974) similar total doses were found to be associated with
myelopathy in patients in which .10cm and . 12cm of the
spinal cord was irradiated. This finding appears to contradict
the early data of Boden. The experimental findings and the
analysis of more recent clinical data suggests the need for a
reappraisal ofexisting clinical guidelines.
Further observations on the relationship between drug
sensitivity in vitro and relapse free interval (RFI) in patients
with glioma
J.L. Darling, D.G.T. Thomas, E.A. Paul & C. Twelves
Institute ofNeurology and University College Hospital,
London, UK.
We have previously described a relationship between
sensitivity in vitro to CCNU or procarbazine (PCB) and RFI
in patients with malignant glioma. We report here a larger
series with more extensive follow-up. One hundred and fifty-
seven patients (63 with grade III and 94 with grade IV
gliomas, age range 18-76) were treated with PCB
(100mgm-2, p.o. days 1-10), CCNU (80mgm-2, p.o., day
1) and vincristine (VCR, 1.5mgm2, i.v. day 1) following
surgery and a course of adjuvant radiotherapy. Chemo-
therapy was administered in 12 cycles at 6 weekly intervals.
Samples were taken at surgery from 56 patients, cultured
and the chemosensitivity obtained to each drug using a 35S-
methionine uptake assay. By comparison of the ID50
obtained for each drug to a large training set of cultures
derived from malignant gliomas it was possible to designate
each patient's culture as either sensitive or resistant to each
of the drugs used clinically. Those with cultures which were
sensitive in vitro to PCB and/or CCNU had a more
favourable prognosis than those whose cultures were not
(Lee-Desu Statistic= 19.2; df=1; P<0.0001). Such a chemo-
sensitivity test may be useful in selecting chemotherapy for
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New developments
Free flap reconstruction for head and neck cancer
M.D. Brough
University College Hospital, London, UK.
The first free flap transfer with microvascular anastomoses
was performed in 1972. During the last fifteen years many
different flaps of composite tissue including skin, muscle,
bone and bowel have been described as suitable for transfer.
The quality of instruments and techniques involved in this
surgery have improved during this time and the success rate
of transfer has now reached a high level.
Free tissue transfer is particulary appropriate in the
management of some head and neck cancers. It provides a
single stage reconstruction following extensive excisional
surgery. The quality of the result is often better than that
hitherto achieved and the distant donor site has a low
morbidity.
Brachytherapy for carcinoma of the oesophagus
K.M. Pagliero & C.G. Rowland
Royal Devon & Exeter Hospital (Wonford), Exeter, UK.
Disappointment with external beam irradiation for palliation
of malignant dysphagia has led us to look at brachytherapy
as an alternative. We have designed an applicator which can
be sited endoscopically under radiological control to treat
oesophageal lesions using the Selectron (Nucletron, Holland)
to load 48 Caesium 137 sources as a 12 cm line source. In
appropriate cases we can treat the entire oesophagus in two
immediately consecutive applications. In our pilot study 72
patients deemed inoperable on grounds of unfitness or
unresectability underwent brachytherapy. Two patients could
not tolerate the treatment. Four-fifths of those treated had
useful improvement in swallowing. Subsequent recurrences in
previous responders were retreated. Twenty per cent of
patients ultimately required intubation. The side effects were
few: mild oesophagitis occurred in a few; 1 patient developed
a radiation stricture which responded to bougienage; 1
patient with tracheal involvement developed a fistula and
would not now be so treated. Adenocarcinoma responded
almost as well as squamous cell carcinoma. Comparison with
our reported experience with intraluminal stenting shows
that brachytherapy has resulted in the elimination of
mortality, considerable reduction in. hospital stay and
complications and an increased survival.
Endoscopic laser palliation for advanced gastrointestinal
cancer
S.G. Bown, L.A. Loizou, K. Matthewson, H. Barr,
P.B. Boulos & C.G. Clark
National Medical Laser Centre, Department ofSurgery,
University College Hospital, London, UK.
Palliative treatment of malignant dysphagia aims to optimize
swallowing as quickly as possible with the minimum of
general distress to these seriously ill patients. We treated 34
patients endoscopically with the NdYAG laser who were
considered unsuitable for surgery due to advanced
malignancy or other major pathology or in whom previous
surgery had been unsuccessful. Two also had radiotherapy.
Significant improvement was achieved in 29 (85%). On a
scale of 0-4 (0=normal swallowing; 4=dysphagia for all
fluids), the mean improvement was 1.7, with 25 patients
(74%) able to swallow most or all solids within a few days
of completion of a course of treatment. Failures were due to
inappropriate patient selection (3) or laser related
perforation (2). The mean survival for the whole group was
19 weeks (range 2-44). Early recurrence (mean 5 weeks) in
13 patients due to exophytic tumour responded to repeat
laser therapy, but late recurrence (mean 10 weeks) in five
patients due to extensive tumour or laser related fibrous
stricturing required insertion of a prosthetic tube.
Endoscopic laser therapy gives rapid relief of dysphagia, but
recurrence is common. A combination of laser therapy with
radiotherapy or chemotherapy could give the best long term
results in these patients.
Endoscopic laser therapy was also used for relief of
bleeding, obstruction, diarrhoea and incontinence in 17
patients with advanced rectal cancers. Significant improve-
ment was achieved in 15 (88%) with minimal morbidity and
no complications. Of 14 who have died (after a mean of 15
weeks) only three had recurrent symptoms requiring further
intervention.
Photochemotherapy: Tumour response and early skin reaction
D. Gilson, D. Ash, I. Driver, J. Feather & S. Brqwn
Departments ofRadiotherapy, Medical Physics and
Biochemistry, Leeds University, UK.
Ten patients with cutaneous or sub-cutaneous recurrences of
malignant disease have been treated with photochemo-
therapy in Leeds. Many have had multiple lesions and have
been treated with varying doses of photofrin II and light.
Thirty-three lesions have been treated with 1.0, 1.5 or
2.0mgkg-1 of photofrin II followed 48-72h later by surface
illumination using red light (630nm) produced by an
argon/dye laser (dose rate 40-172mWcm-2). A range of
doses from 25-100Jcm-2 was delivered.
Only complete responses of the tumour were scored
together with severe skin reaction which was associated with
the formation of a black eschar.
With increasing doses of photofrin II and increasing doses
of light irradiation complete tumour response steadily
increased. This was, however, almost paralleled by the
incidence of skin necrosis suggesting that there is a relatively
low therapeutic ratio for superficial skin illumination in
photochemotherapy. Skin necrosis caused little or no
discomfort to patients, however, and eventually healed in all
cases.
The use of interstitial light delivery by implantation of
optical fibres has been initiated to try and improve the
therapeutic ratio and this may also increase the range of
lesions amenable to treatment.
Induction of necrosis in an experimental mouse lymphoma
using modifiers of tumour oxygenation and a bioreductive
drug.
C.H. Du Boulay, G.E. Adams, I.J. Stratford, S. Butler &
J. Nolan
MRC Radiobiology Unit, Chilton, Didcot, UK.
Oxygenation in even small tumours can be substantially less
than in surrounding normal tissues. This can be exploited in
the design and application of drugs which rely for their anti-
tumour effect on reductive activation. The efficiency of such
agents can be greatly increased by substances that further
decrease tumour oxygenation.
This paper describes a histological study of the induction
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an experimental T-cell mouse lymphoma. Tumour-bearing
mice were treated with the vaso-active drug, hydralazine,
either alone or in combination with nitroheterocyclic
bioreductive drugs including the bifunctional compound
RSU 1069. Normally, histological sections of infiltrated
lymph nodes show no necrosis although studies with tritium-
labelled misonidazole show that some degree of hypoxia is
present. Treatment with either single or multiple doses of
hydralazine caused some tumour necrosis. Combinated
treatment with both hydralazine and RSU 1069 caused
massive necrosis and tumour shrinkage. In some cases, no
residual viable tumour cells were visible in the nodes.
Extensive reduction of tumour load also occurred in
infiltrated liver and spleen.
Vascular collapse: A component of tumour therapy?
J.C. Murray, V.S. Randhawa & J. Denekamp
CRC Gray Lab., Northwood, UK.
Tumours are frequently poorly nourished due to inadequate
vascular supply. This deficiency may have important
consequences both for chemotherapy, where delivery of
drugs to distant cells may be suboptimal, and for radio-
therapy, as hypoxic cells are known to be radioresistant. We
are interested in whether this deficiency can be exploited to
therapeutic advantage, and are currently examining the
effects of various forms of therapy on vascular structure and
function in experimental tumours.
Vascular function has been assessed in the SaFA murine
sarcoma using a fluorescent dye perfusion technique.
Hoechst 33342 was injected i.v. into tumour-bearing mice
and allowed to circulate for 1 min. After sacrifice, tumours
were removed, frozen and sectioned at 6Hm. The distribution
of Hoechst dye was assessed by Chalkley point counting of
sections viewed microscopically under epi-fluorescence.
Sections were also stained using the immunofluorescent
technique with an antibody to mouse laminin to delineate
the basement membrane of tumour blood vessels, allowing
the estimation of total vascular volume. Using these
techniques we examined the effects of chemotherapy, in rhe
form of combined melphalan and misonidazole (MISO), as
well as varying single doses of X-rays (10-40Gy), and
attempted to correlate vascular effects with tumour response
in terms of regrowth delay.
A combination of melphalan and MISO which induced a
2 week growth delay also caused a profound decrease in
effective vascular volume within 24h after treatment. This
vascular effect was shown to be largely due to the MISO,
although MISO alone did not affect tumour growth. Doses
of X-rays which induced a growth delay similar to that from
the combined drugs did not decrease vascular volume
significantly at any time after treatment, as assessed by
Hoechst perfusion alone.
We conclude that the contribution of vascular collapse to
tumour growth delay may vary with different forms of
therapy.
Rectal tumours
External beam radiotherapy for rectal adenocarcinoma
R.E. Taylorl, G.R. Kerrl & S.J. Arnott2
'Department ofClinical Oncology, Western General Hospital,
Edinburgh; and 2St. Barthelomew's Hospital, London ECJ,
UK.
Between January 1974 and December 1983, 243 patients with
rectal adenocarcinoma were treated with external beam
pelvic radiotherapy; 74 were treated with radical radio-
therapy for inoperable or recurrent disease; 145 with
advanced pelvic tumours or metastases were treated
palliatively; 24 with small volume residual pelvic tumour or
who were felt to be at high risk of pelvic recurrence
following radical resection received postoperative
radiotherapy. Between 1974 and 1977 46 patients (radical:
16, palliative: 30) received 5 fluorouracil (5FU) 250mg daily
with each fraction of radiation. Actuarial survival at 2 years
was 29.0% for inoperable, 31.6% for recurrent, 10.2% for
palliative and 62.1% for postoperative patients. Survival was
significantly better for patients with small (.5cm) tumours
(P<0.001).
Complete tumour regression was observed in 38% of
radically treated and 24% of palliatively treated patients,
and partial regression in 56% of radically treated and 58%
of palliatively treated patients. Survival was significantly
better for patients responding completely to radiotherapy
(P<0.001). Long term local control was more commonly
observed for small tumours. Symptomatic response was
observed in 75% of radically treated and 77% of palliatively
treated patients.
The addition of 5 FU did not appear to improve survival
or local control. Fifty-eight per cent of patients treated
postoperatively remained free of local recurrence.
Benefits expected from conformation radiotherapy in the
treatment of pelvic tumours
D. Tait', A. Nahum2, C. Southall' & J.R. Yarnold1
Departments of1Radiotherapy and 2Physics, Royal Marsden
Hospital, Surrey, UK.
In cancers of the bladder, prostate and cervix, the radiation
dose that can be delivered by conventional beam
arrangement is limited by bowel tolerance. The scope for
adapting the shape of the high dose volume to conform
more closely to that of the tumour volume is being
investigated in (15) patients with bladder cancer by
exploiting the independent collimator movement available on
the Philips SL-25 linear accelerator. One cm CT slices, taken
through the pelvis with the patient in the treatment position,
are used to reconstruct tumour, rectal and bowel volumes
included in the treatment length. From the CT scans, a
conventional small volume treatment plan is devised using a
three field arrangement. The same treatment length is then
divided into three horizontal segments, the dimensions of
which are adjusted to encompass tumour volume with
maximum exclusion of normal bowel. Keeping the same
gantry angles, three fixed fields are used to cover the
segmented treatment volume by employing the collimator
sweep in the long (Y) axis, combined with the cross axis
collimator facility. This is a simple manoeuvre which could
be implemented immediately on the Philips SL-25.
Cumulative volume dose distributions of a typical conformal
plan compared to the corresponding conventional
distribution show a 25% reduction in the overall treatment
volume (defined by the 50% isodose) which includes up to
50% reduction in the volume of rectum and bowel in the
high dose zone. The potential therapeutic gain of the
conformal plan will be discussed.SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 869
Louise Buchanan Memorial Lecture
The curative treatment of rectal cancer with radiotherapy (RT)
J.-C. Horiot
Cancer Institute Georges-FranCois Leckerc, 21034 Dijon,
France.
Few rectal carcinomas can be satisfactorily treated with
surgery alone, viz. medically operable patients with
Dukes/Gunderson Sosin A, B1 treated by anterior resection.
All other clinical presentations will benefit from RT as part
of, or as the single treatment. This provocative statement is
now supported not only by a number of historical series, but
also by at least three randomized trials in the United States
and Europe (GITSG 71-75, EORTC 40761, NCCTG-Mayo).
Loco-regional failure rate is significantly reduced by either
pre-operative or post-operative RT. Trends and even
improvement in survival are obtained in subsets of patients
of the RT arms.
Limited, accessible, exophytic rectal adenocarcinomas are
indications for intracavitary RT techniques (X-ray 50kV
contact RT with or without interstitial Ir 192 brachy-
therapy): a 90% cure rate is achieved in J. Papillons' work
as well as in our own material in these cases, with sphincter
preservation. We have described a clinical staging for non-
fixed rectal cancers: a significant correlation (P=0.001) is
obtained between the staging criteria and disease free
survival rate.
The latest development in this area is the concept of
conversion of a classical indication of abdomino-perineal
surgery into a sphincter saving management: 2 months after
a 30Gy in 10 fractions and 2 weeks external radiotherapy is
given, a decision is taken either to proceed with abdomino-
perineal surgery, or with low anterior resection, or with a
boost dose of RT (usually with interstitial Ir 192):
Both J. Papillon's experience and our own data
demonstrate that 60% of the patients with moderately
advanced low rectal cancer can be cured with the
preservation of a functional sphincter.
Posters
Epirubicin versus mitozantrone in advanced breast cancer
S.N. Larsson, G. Blackledge, A. Chetiyawardana, T. Latief,
J. Mould & M. O'Brien
adriamycin, each in combination with methotrexate and
cyclophosphamide as an i.v. pulse every 3 weeks. The 'low-
risk' group are randomised between epirubicin, mitozantrone
and adriamycin as single agents every 3 weeks. Weighted
randomisation is used so that 40% of patients receive the
novel agents and 20% receive adriamycin. Objective
assessment of response rates, duration and toxicities are
made using WHO criteria. By March 1st, 1987, 90 patients
were randomised: 70 into the 'high-risk' group and 20 into
the 'low-risk' group. It is hoped to close the trial when 250
patients have been randomised. The rate of accrual has been
fairly constant 10 patients per month.
Sequential chemotherapy, surgery and radiotherapy in locally
advanced breast cancer
I.R. Campbell, J.A. Green, R.D. Errington, S.J. Leinster,
S. Myint & H.M. Warenius
CRC Department ofRadiation Oncology, Clatterbridge,
Wirral, UK.
Thirty-seven patients with T3b, T4, N2 or N3 advanced local
breast cancer were treated with 3-6 cycles of vincristine
1.4mgm 2, doxorubicin 40mgm-2 and cyclophosphamide
600mgm-2 i.v. with an overall response rate of 67%.
Fourteen patients had received a trial of hormone therapy,
but no patient had been given prior cytotoxic chemotherapy
or radiation therapy. In no case was chemotherapy
discontinued on account of toxicity. Where gross disease
remained (>3cm), mastectomy (10 patients) or local
excisions (5 patients), was carried out, and 32 patients then
received radiotherapy, 57Gy in 24 fractions to the breast
with boost to the tumour site. Complete clinical remission
was achieved in 19% of patients after chemotherapy, in a
further 30% after surgery, and in a further 27% by radiation
therapy, giving an overall remission rate of 86% and a total
complete remission rate of 76%. Of the 10 patients with N3
disease, half were dead within 1 year. The survival rate in
the entire group was 50% at 2 years. The median time to
relapse in the 28 complete responders was 17 months. Local
palliation, defined as absence of pain, ulceration or an
enlarging mass was achieved in 92% of the total number of
patients, and in 60% of the patients surviving 2 or more
years from the start of treatment. This an effective and
tolerable approach for a sub-group of breast cancer patients
with complex management problems.
CRC Clinical Trials Unit, Birmingham, UK.
A trial was designed to investigate two new anthracycline
cytotoxics, alone and in combination, in advanced breast
cancer.
Published data suggest that factors predicting poor
response and survival exist in patients starting chemotherapy
for advanced disease. In our own multivariate analysis,
interval of under two years from diagnosis (P=0.006) and
presence of visceral metastases (P=0.029) were significant. It
may be appropriate to reserve aggressive combination
chemotherapy for patients exhibiting poor prognostic
factors.
This trial separates patients with objectively assessable
disease into groups: a 'high-risk' group below age 70 years
with visceral metastases or an interval of under two years
between diagnosis and starting chemotherapy, and a 'low-
risk' group of patients falling outside these criteria. To be
accepted, patients must be off hormone therapy and must
not have had previous chemotherapy. The 'high-risk' group
are randomised between epirubicin, mitozantrone and
Medroxy progesterone acetate: Variation in serum
concentration achieved with three comercially available
preparations.
A.D. Stockdale & A.Y. Rostom
St. Luke's Hospital, Guildford, UK.
Twenty-nine females with metastatic or locally recurrent
carcinoma of the breast were treated with 1 g medroxy-
progesterone acetate (MPA) daily by mouth. This was used
as a second or third line treatment. Serum concentration of
MPA was measured over a 28 day period. We have
demonstrated a significantly greater area under the
concentration time curve, peak and steady state MPA
concentration, for provera 100mg and 200mg (Upjohn) than
farlutal 500mg tablets (Farmitalia). Relative bioavailability
of preparations should be considered when prescribing or
assessing treatment results when MPA is used.870 SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
Cyclical sequential hormonochemotherapy for the treatment of
advanced breast cancer
M.W. Ghilchik, M.J. Reed, N. Shaikh & P.A. Beranek
Breast Clinic, St. Mary's Hospital, Praedt St., London W2,
UK.
Endocrine or chemotherapy is widely used in the treatment
of advanced breast cancer. In order to improve the relatively
constant response rates to such therapy, however, it has been
proposed that endocrine and chemotherapy should be
combined and we are currently investigating the use of
cyclical sequential hormonochemotherapy (CySHoC).
Hormone therapy was initiated with ethynyloestradiol
(10,ugday-1) for 1 week after which patients received
medroxyprogesterone acetate (500mgday-1) for 2 weeks. At
the end of the first 3 week period patients received a bolus
injection of vincristine (2mg) and an infusion of adriamycin
(50mg). The hormone therapy was then repeated after which
an infusion of cyclophosphamide (500mg), methotrexate
(50mg) and 5-fluorouracil (500mg) was given. This
treatment formed 1 double cycle and patients received 3
double cycles of CySHoC in all. So far 34 out of 40 patients
with advanced breast cancer entered into this trial,
irrespective of ER status, and completed 3 double cycles of
CySHoC (85%). Of these 34 women, 16 (47%) showed a
complete response, according to UICC criteria, 15 (44%) a
partial response with only 3 (9%) failing to show any
response. The disease free interval for patients showing a
complete response (22+7 months) was significantly longer
(P<0.001) than for those showing only a partial response
(5+4 months).
It is concluded that the use of cyclical sequential
hormonochemotherapy may offer significant advantage for
the treatment of advanced breast cancer than the use of
endocrine or chemotherapy alone.
A simple, effective approach to the infusion of epirubicin
S.R. Ebbs, J.A. Saunders, J.V. Roberts, T. Bates &
M. Baum
Departments ofSurgery, Kings College Hospital, London and
William Harvey Hospital, Ashford, Kent, UK.
Anthracycline acute and chronic toxicity depends upon the
peak plasma dose of the drug, whilst response rate appears
to be independent and may be improved by prolonged
exposure to low doses.
Infusion therapy has previously been considered difficult.
However, by inserting Hickman catheters and maintaining
them without routine dressing and only flushing them weekly
with normal saline, we have reduced both cost and time.
Rather than heavy, expensive mechanical pumps, infusions
through the catheters have incorporated 'Travenol Infusors'.
These are small, light disposable cylinders. Both the force to
propel and a reservoir for the solution are provided by an
elastomeric balloon.
To determine the merits of this method we are conducting
a randomised trial of weekly epirubicin, given either by 24h
infusion or bolus injection. So far 33 patients with advanced
breast cancer are assessable, 14 have received infusion
therapy using a total of 149 infusors. There have been no
mechanical failures by the infusor.
Toxicity Infusor (n=14) Bolus (n=19)
Myelosuppression 1 3
Nausea and vomiting 2 9 P<0.01 Fishers exact test
Infusors reduce acute toxicity; treatment time has
decreased and needle phobia and the risk of extravasation
have not been encountered. There have been no cases of
cardiotoxicity. Infusion anthracyclines offer safe, less toxic
chemotherapy with an improved quality of life.
A high dose tamoxifen regimen
N.A. Shaikh & M.W. Ghilchik
Breast Clinic, St. Mary's Hospital, Praed St., London W2,
UK.
Twenty-five postmenopausal patients (age range 63-90 years,
mean 73 years) with locally advanced breast cancer (stage III
and IV) were treated with a high dose of tamoxifen of
100mg daily for a week, followed by a maintenance dose of
40mg per day. Compliance was 100%. Tumour tissue from
14 of the 25 patients (56%) was assayed for hormone
receptors. The diagnosis was confirmed on a Trucut biopsy.
Each patient had a full blood count, biochemical profile, a
chest X-ray, ultrasound scan of liver and a bone scan.
At two weeks follow up 8 patients (32%) showed a good
response (-50% decrease in tumour size), 9 patients (36%)
showed a moderate reponse (-25% decrease in tumour
size), but 7 patients (28%) showed a poor or no response.
The patients were followed up for a period of 4 months to
two years (mean 9.6 months). Seven patients who had not
responded at two weeks, did not show any response at 2
years follow-up and in 3 of these 7 non-responders the
tumour size increased.
The high dose regimen may help to differentiate early the
group of patients who are unlikely to respond to tamoxifen
so that they can be treated by an alternate method early
rather than late.
Breast cancer and melanoma - A clinical proposal
J.B. Healy
St. Luke's Hospital, Dublin 6, Ireland.
Breast cancer is compared to malignant melanoma of the
lower limb. Recurrence patterns for melanoma are either
local, within a short distance of the primary growth, or
diffuse in the thigh. The latter only occurs when lymphatic
glands are invaded and when drainage is obstructed by
surgery or tumour mass. A second primary is a separate
matter. The same pattern occurs in breast cancer. Chest wall
recurrences are due to blocked drainage or dermal back flow
and this occurs only when lymph nodes have been invaded.
Local spread from surgical excision is as for melanoma.
After mastectomy, radiation is only useful if the nodes were
invaded. After tylectomy, if the glands were positive, then we
need to treat the local lymphatic system but if negative, only
the area around the excision.
An attempt is made to justify this view from the literature,
from clinical cases and from lymphograms and
lymphoscintograms.SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 871
A phase II evaluation of 4'-epi-doxorubicin (Epirubicin) in
small cell lung cancer
J.R. Johnson & D.A.L. Morgan
Hogarth Centre ofRadiotherapy and Oncology, Nottingham,
UK.
Twenty-four patients with small cell lung cancer (SCLC),
none of whom had received prior anthracycline treatment,
were given Epirubicin as a single agent. In 14, an initial dose
of 50mgm-2 was used ('low dose'); the others received
100mgm-2 ('high dose'). Cycles were repeated at three-
weekly intervals with a dose escalation of 25mgm-2 for the
second or subsequent cycles when deemed clinically
appropriate.
Response was assessed by WHO criteria and is tabulated
below:
Initial dose Progressive disease No change Responders
50mgm-2 11 2 1
100mgm-2 3 2 5
Grade 3-4 toxicity was seen in 12 patients (6 from each
group) being due mainly to alopecia (all 12 patients) and
thrombophlebitis (6 patients). Gastrointestinal toxicity of
this grade was only seen in the 'high dose' group: persistent
nausea and vomiting in 2 patients and severe mucositis in 1
patient. On no occasion did treatment have to be delayed or
adjusted because ofmyelosuppression.
The degree of toxicity is acceptable, particularly at the
'low dose'; however the overall response rates indicate that
epirubicin is an effective agent against SCLC only at doses
at or above 100mgm-2.
Lung carcinoma: Observations on changing phenotype and
common biological properties
G.M. Duchesne, J.J. Eady, J.M. Peacock, M.F. Pera &
G.G. Steel
Institute ofCancer Research, Sutton, Surrey, UK.
Recent studies of the biological properties of human lung
cancer cell lines have suggested major distinctions between
the neuro-endocrine small-cell carcinomas (SCC) and other
tumour types (non-SCC). This study set out to investigate
these properties further and examine the relationships
between the cell types.
A total of 13 tumour lines were derived from patients and
their morphology, biochemical profiles, intermediate filament
(IF) expression, hormone production and ultrastructural
features examined. All cell types were found to express
endocrine peptides although this was most marked in SCC.
Study of the IF showed that all cell types could express both
epithelial and neural IF. In addition 3 cell lines have shown
alterations in morphology and biochemical properties during
successive passages to different cell types. These findings are
in keeping with the concept of a common cell of origin, and
may have important implications for clinical response to
therapy.
High dose rate brachytherapy in the treatment of lung tumours
C.G. Rowland & K.M. Pagliero
Postgraduate Medical School & Royal Devon and Exeter
Hospital, Exeter, UK.
Our initial experience in the treatment of oesophagus
carcinoma (120 cases) has proved encouraging in terms of
palliation and perhaps surprisingly a number of 1-2 year
survivors exist having only had intra-cavitary irradiation. We
have used all 48 sources of a low dose rate Selectron to give
15-20Gy in 1-2h. Here, we appear to be out of the range of
dose rate effect which appears negligible. The catheter
diameter, however, limits its use at other sites. In
conjunction with Nucletron (UK & Holland) a high dose
rate micro-Selectron has been developed passing a 10Ci
iridium source through up to 18 catheters 2mm in diameter.
Our early experience in treatment at various sites particularly
lung will be described and the great potential for treatment
including cost effectiveness discussed.
The effect of hemi-body irradiation on immunoglobulin and
f12-microglobulin levels in drug resistant myeloma
B.J. Smith, A. Norden, J.S. Tobias, J. Richards &
C.R.J. Singer
University College Hospital, London, UK.
Hemi-body irradiation (HBI) is an effective treatment for
symptoms relating to advanced drug-resistant myeloma and
macroglobulinaemia. We have already noted that immuno-
globulin levels may fall after treatment with HBI (Tobias et
al., Radiother. Oncol. 3, 11, 1985) and we have now reviewed
20 patients, all with drug resistant disease, in whom we have
complete sequential data analysing pre- and post-treatment
immunoglobulin levels. In addition, 7 of these patients have
had serial estimation of f2-microglobulin (fi2m) before and
after HBI. Fifteen patients had IgG myeloma, 3IgA and 2
IgM. Fourteen were treated with upper-HBI (U-HBI) (mean
dose 7.7Gy) and 14 had lower HBI (L-HBI) (mean dose
9.3Gy). Eight patients were treated to both halves of
the body. All of these 20 patients had a fall in circulating
immunoglobulin level, with an average fall of 13gl-' in the
abnormal paraprotein. This effect was similar for both
U-HBI and L-HBI fractions. As a percentage of the total
abnormal paraprotein measured just prior to HBI treatment,
this represents a mean fall of 42% for patients with IgA
myeloma, 36% for IgM and 23% for IgG.
Eight patients died of progressive myeloma within an
average of 6.7mth, but without the immunoglobulin
returning to pre-treatment levels. Twelve patients lived long
enough for their immunoglobulin to return to pre-HBI level;
this occurred after a mean of 12.7mth. By contrast, in 7
patients (all with IgG myeloma) in whom we measured the
fi2m before and after HBI, we could not demonstrate any
change in the level, despite the mean fall of 11 gI1 in the
IgG per HBI fraction. Five patients remain alive and well at
periods >2 years from HBI.
Autologous bone marrow transplantation (ABMT) in acute
leukaemia
J.G. Gribben, A.H. Goldstone, D.C. Linch, J.D.M. Richards
& L. Dones
Joint Department ofHaematology, University College and
Middlesex Hospitals, London, UK.
We have applied the same chemotherapy treatment protocol
at a single centre to 64 patients with acute leukaemia using
combination chemotherapy for bone marrow ablation. The
response to high dose chemotherapy and ABMT and its
associated morbidity and mortality have been compared in
39 patients with AML and 25 patients with ALL.
Thirty-one patients with AML were treated with ABMT
during first complete remission (CR) and 22/31 (70%)
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months. Fourteen of 31 patients have received double grafts
and all remain in unmaintained remission, median follow-up
32 months.
Twelve patients with ALL were treated in first CR. Only
3/12 (25%) remain in unmaintained remission at 15, 16 and
36 months post ABMT. Two patients in this group relapsed
late after transplant at 32 and 33 months respectively.
In patients treated after first remission of disease only 2/21
(9.5%) remain disease free at 32 and 56 months post ABMT,
both patients having ALL in second CR. Seventeen of 21
(81%) have died of recurrent leukaemia.
We find this protocol worthy of further study in AML in
first CR, but have abandoned this approach in other groups
with acute leukaemia.
Immunocytochemistry - Its value in cancer diagnosis and
management
E. Heyderman' & T. Joannides2
Departments of1Histopathology and 2Radiotherapy, UMDS,
St. Thomas Hospital, London, UK.
The use of immunocytochemical techniques in tumour
pathology is well established, and may be essential for
precise classification. With the advent of more effective
treatment modalities, accurate diagnosis has become even
more important for cure, for long term remission, and for
effective palliation. Our interest has been predominantly in
those tumours which presented with metastatic deposits and
an unknown primary site. We have also studied tumours of
adjacent organs such as the prostate and bladder, and the
prostate and rectum, where it has been difficult on purely
morphological grounds to determine the organ of origin. We
are in the process of following up 140 patients whose
tumours have given rise to problems in histopathological
diagnosis. An immunoperoxidase technique has been used
for the localisation in formalin-fixed paraffin-embedded
sections of a variety of mainly epithelial markers, including
carcinoembryonic antigen (CEA), epithelial membrane
antigen (EMA), cytokeratin (CAM 5.2), DD9-E7, S100, and
prostatic acid phosphatase. Twenty-five were deposits in
bone, 20 in lymph nodes, 26 were pleural or pulmonary
lesions, 11 were hepatic deposits, 31 were ?prostate ?bladder,
and there were 38 from other sites. Most success was
achieved in the diagnosis or exclusion of the prostate as the
primary site. It was also possible to exclude certain sites such
as stomach, pancreas, colon, or kidney, so avoiding
unneccesary radiological and/or invasive investigations, with
important implications in terms of patient management and
care.
Salvage therapy in relapsed Hodgkin's disease by high dose
chemotherapy and autologous bone marrow transplantation
(ABMT) - Outcome and indications
J.G. Gribben, A.H. Goldstone, D.C. Linch, R.L. Souhami,
G. Vaughan-Hudson & J.S. Tobias
Departments ofHaematology and Radiotherapy, University
College Hospital, UK.
Thirty-eight patients with advanced relapsed Hodgkin's
disease have been treated by high dose chemotherapy and
ABMT in our centre. There were 30 males and 8 females.
The median age was 29 years. No patient had previous bone
marrow involvement. Three patients had failed to achieve
complete remission (CR) with first-line alternating
chemotherapy (LOPP/EVAP). The remaining 35 patients had
received at least two regimens of salvage therapy including
localised radiotherapy in 18 patients.
Four patients died of sepsis during the neutropenic phase.
Eighteen patients entered CR post ABMT, 4 further patients
showed partial response and only two patients have shown
no response to high dose therapy. Those who achieve CR
have a significant improvement in overall survival over those
who do not.
Analysis of BNLI data identifies 3 groups of patients who
may benefit from ABMT. Poor prognosis patients who fail
first line therapy, failure to alternate firstline therapy and
failure of any two sequential modalities of therapy.
Most of our patients were grafted with disease too
advanced to achieve a respectable result from ABMT. In the
future it seems more appropriate to investigate the role of
ABMT versus conventional therapy in poor risk patients.
Optimization of treatment for primary non-Hodgkin's
lymphoma of the brain
A.R. Gershuny, H.J.G. Bloom & A. Horwich
Royal Marsden Hospital, London and Surrey, UK.
Primary non-Hodgkin's lymphoma of the brain is a rare
disease accounting for less than 2% of intracranial tumours.
It appears to behave in a far more aggressive manner than
its extracerebral counterpart. Recently there have been
reports of a marked increase in its incidence in immuno-
suppressed individuals; particularly those with the Acquired
Immune Deficiency Syndrome.
The natural history and treatment of 15 cases of primary
non-Hodgkin's lymphoma of the brain presenting between
1974 and 1986 is reviewed. Most cases showed a rapid
response to treatment. Mean survival was only 17 months
ranging from 3-55 months with 8/15 patients dying from
CNS relapse and 3/15 from incontrolled systemic disease.
The role of surgery, chemotherapy and radiotherapy is
discussed. The optimal treatment of this disease remains
elusive and the investigation of alternative methods of
treatment is warranted.
A retrospective evaluation of radiotherapy as a curative agent
in localised Hodgkin's disease
B.V. Hudson, G.V. Hudson, M.H. Bennet, K.A. MacLennan
& A.M. Jelliffe
British National Lymphoma Investigation, London, UK.
An analysis was made of over 750 patients with Hodgkin's
disease entered into BNLI studies over the last 15 years.
These patients were pathologically or clinically staged I or II
with upper half disease, with or without systemic 'B'
symptoms, and were histologically graded as being LP, MC
NS grade I, and NS grade II.
The disease free survival, survival from 'salvage' therapy,
and the overall survival of these patients was determined,
together with their relationship to various prognostic factors.
The success of both initial treatment and 'salvage' therapy
was found to be related to prognostic factors, with LP and
MC histology being related mainly to the presentation
lymphocyte count, and nodular sclerosis to the presentation
ESR, the histological grade, and the presence or absence of
mediastinal involvement.
The overall survival of patients who were over 60 years of
age at presentation was significantly worse than that of
younger patients. Patients requiring 2nd line treatment who
failed to obtain complete remission from it had an extremely
poor survival.SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION 873
The results of treatment of adenocarcinoma of cervix by
radiotherapy
R.P. Symonds, S.E. Davidson, D. Lamont & E.R. Watson
Western Infirmary, Glasgow, UK.
Adenocarcinoma of the cervix has been thought to be less
responsive to radiotherapy than the more common
squamous tumours. Between 1964 and 1980 1,505 (90.3%)
patients with squamous tumours and 95 (5.7%) with adeno-
carcinomas were treated by radical radiotherapy. The
treatment given to either histological type assigned to the
same tumour stage was identical.
The actuarial 5-year survival (all stages) of patients with
squamous tumours was 53.2% and with adenocarcinomas
was 48.5%. When survival is analysed by tumour stage and
patient age, survival is very similar for patients with either
tumour type.
Percentage 5-year survival of adeno and squamous carcinoma
ofcervix
Adeno Ca Squamous Ca
Stage I 81.8 79.6
Stage II 54.9 59.8
Stage III 29.7 38.4
Stage IV 20.9 8.9
Chemotherapy prior to radical radiotherapy for Stage Ill and
IV carcinoma of cervix
R.P. Symonds, E.R. Watson, T. Habeshaw & S.B. Kay
1933, 1978) with single agent cis-platinum in the
management of patients with no macroscopic disease after
primary surgery. Between November 1981 and November
1986, 37 patients were randomised to receive either pelvic
plus abdomino-pelvic irradiation, using the moving strip
technique (2250cGy midplane; total dose to pelvis 4500cGy)
or 5 courses of single agent cis-platinum (100mgm-2 i.v.
every 21 days). Eighteen patients were randomised into the
radiotherapy arm and 19 received chemotherapy. The two
groups were comparable for age, tumour histology and
differentiation, and FIGO staging (Ic to III). Three of 19
patients, all in the chemotherapy arm, did not receive full
protocol therapy (2 patients received only 4 courses because
of toxicity; 1 patients received 5 courses but at reduced
dosage.) The study group has had a median follow-up of 37
months (range=2-63mo.) and median survival is 48 months.
There have been 6 disease related deaths and 1 unreleated
death in the radiotherapy group; progressive disease was
noted at the end of treatment in 3/6 of the disease related
deaths. There have been 3 deaths in the chemotherapy
group. There is no significant difference in survival between
the two groups (log rank chi square (1 df)= 2.27; P=0.132).
One patient in the chemotherapy group has evidence of
recurrent disease. Four patients in the radiotherapy arm
have experienced radiation induced complications requiring
surgical management. These preliminary results attest to the
favourable prognosis of patients with no macroscopic disease
following primary surgery. At this stage, there is no
significant survival difference between the two groups,
although there is long term morbidity from significant
radiation induced enteritis. Further follow up is required to
determine whether cis-platinum will continue to give results
comparable with those achieved by radiotherapy in the study
of Dembo et al.
Western Infirmary, UK.
The 5-year survival of patients with Stage III or IVa is 30%
and 8% respectively. In order to increase local control and
subsequent survival of patients with advanced carcinoma of
cervix, 28 patients with Stage III and 15 patients with Stage
IVa squamous tumours received 2 pulses of chemotherapy
before full dose radical radiotherapy (RT). before
chemotherapy, tumour was estimated by ultrasound and
during an EUA. Cis-platin 50mgm 2, bleomycin 30mg and
vincristine 2mg i.v. were given on day 1 and day 14.
Response to chemotherapy was assessed on day 28 at the
start of RT by ultrasound and clinical examination. 42.5Gy
was given in 20 fractions over 4 weeks using 4meV X-rays
to the true pelvis (average field size 15 x 15 x 12cm) followed
by a single Cs 137 insertion (A point dose 33.5Gy). Twenty-
two of 41 (54%) had a partial response to chemotherapy.
The 3-year actuarial survival is 52%. Responders to chemo-
therapy have a better prognosis than non-responders: at 36
months 71% are tumour free compared to 31% of non-
responders to chemotherapy (P=0.016). Acute and late
effects of radiotherapy were not increased.
Randomised trial comparing abdomino-pelvic radiotherapy
with cis-platinum in patients with ovarian cancer with no
macroscopic disesase after primary surgery
C.W.E. Redman, F.D. Lawton, D. Luesley, C. Hilton,
J. Mould, D. Spooner, T. Latief, K.K. Chan &
G. Blackledge
C.R.C. Clinical Trials Unit, Queen Elizabeth Hospital,
Birmingham, UK.
The objective of this study was to compare radiotherapy, as
described by Dembo et al. (J. Rad. Oncol. Biol. Phys., 5,
Surgery for malignant extradural tumours of the spine
P.L. Turner, H.G. Prince, J.K. Webb & M.P.J.W. Sokal
University Hospital, Nottingham, UK.
Sixty-three patients with malignant extradural tumours of
the spine have been treated surgically for spinal cord
compression or uncontrolled back pain. Anterior surgery was
used in 37 cases, posterior surgery in 22 cases, and in 4 cases
combined or staged anterior and posterior decompression.
The medical oncologists were involved in the assessment
of the patients on presentation and adjuvant therapy was
used post-operatively where this was considered appropriate.
Anterior surgery showed major neurological recovery in
54.5% of cases; only 12.1% of patients remained unchanged;
the remaining patients improved neurologically but not
sufficient to allow them to walk or to regain bladder
function. posterior surgery achieved major neurological
recovery in 33.3% of cases; over 44% were unchanged.
Back pain was improved in 73% of those undergoing
anterior surgery, and 54% after posterior surgery. The
complication rate was similar for the two groups. Five
patients died from surgical complications; 36 had died with
disseminated carcinoma at the time of review; mean survival
in this latter group being 4.1 months. Twenty-two patients
are still alive with 17 satisfactory with a mean survival of
14.2 months. Surgery did not give major improvement in the
patients presenting with complete paraplegia.874 SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
Endocrine disorders following treatment of brain tumours in
childhood
E.A. Livesey, C.G.D. Brook, A.C. Whitton, J.S. Tobias &
H.J.G. Bloom
Middlesex, University College and Royal Marsden Hospitals,
UK.
One-hundred and twelve children (47 girls and 65 boys)
treated for brain tumours were studied to assess the
prevalence of endocrine disorders other than growth
hormone deficiency. All had tumours remote from the
hypothalamus or pituitary and were clinically disease free at
the time of the study. All had received cranial irradiation, 73
spinal irradiation and 34 adjuvant chemotherapy. Cytotoxic
agents were lomustine, vincristine and methotrexate. Mean
age at treatment was 6.7 years (1-15). Mean follow-up
postradiotherapy was 8.5 years.
Thyroid dysfunction was identified in 29%. Twenty-nine
had elevated basal serum TSH concentrations with mean
total serum thyroxine of 76.3nmoll-1(10-118). Four had
secondary hypothyroidism. There was a highly significant
association between exposure to chemotherapy and elevated
basal serum TSH concentrations, P<0.001, and a less
significant association with spinal irradiation alone, P<0.05.
Primary gonadal dysfunction was found in 17%, 16 girls
and 4 boys. Ovarian damage was associated with spinal
irradiation and with a younger age at treatment. Primary
testicular damage was only associated with chemotherapy
particularly lomustine. Hypogonadotrophic hypogonadism
was rare (6%).
ACTH deficiency was found in 4 out of 85 children
assessed.
The effects of dexamethasone in patients with brain tumours
R.P. Beaney, K.L. Leenders & D.J. Brooks
Queen Elizabeth Hospital, Birmingham & National Hospital
for Neurological Diseases, London, UK.
Dexamethasone is thought to exert its beneficial effect by
reducing perifocal oedema in patients with brain tumours.
Clinical improvement, however, commonly occurs before
there is any detectable decrease in perifocal oedema. Recent
magnetic resonance imaging studies failed to show any
decrease in peritumour oedema after the administration of
dexamethasone, despite obvious clinical improvement. We
set out to see if there was any circulatory cause for this
improvement
Using positron emission tomography we measured
regional cerebral blood flow (rCBF) and regional cerebral
blood volume.(rCBV) in 10 brain tumour patients within 5
days of starting dexamethasone. Regional CBF and rCBV
both decreased in a coupled fashion. The mean decrease in
rCBF for the whole brain was approximately 15% and the
mean decrease in rCBV for the whole brain was 13%.
We think that the initial beneficial effect of
dexamethasone is partly mediated through vasoconstriction
of cerebral vasculature. Glucocorticoids may cause vaso-
constriction by inhibiting the release of prostaglandins, e.g.
prostacyclin (a potent vasodilator) from vascular endothelial
cells. The magnitude of the clinical response, however,
depends very much on the brain tissue compliance of
individual patients.
Chemotherapy for thyroid cancer
P.J. Hoskin & C.L. Harmer
Royal Marsden Hospital, Sutton, Surrey, UK.
The place of chemotherapy in advanced progressive thyroid
cancer is controversial and there are few reported series of
its efficacy in this setting.
Twenty-nine patients with primary carcinoma of the
thyroid have been treated with sequential chemotherapy
regimes using the single agents etoposide, carboplatin, cis-
platinum or methotrexate and the combination of
adriamycin, bleomycin and vincristine (ABC). Indications for
chemotherapy were symptomatic recurrent or metastatic
disease from follicular, papillary or medullary carcinomas
unresponsive to conventional treatment, or advanced
anaplastic carcinomas. A total of 60 individual drug
exposures have been evaluated in these 29 patients.
Fourteen of 29 patients (48%) responded to one or more
agents: 4/22 responded to etoposide, 2/9 to carboplatin, 5/13
to cis-platinum, 1/3 to methotrexate and 5/13 to ABC. One
complete response was seen following etoposide. Significant
drug toxicity occurred in 8 patients. Mean survival in
responders was 19 months and in non-responders 5.4
months.
Etoposide, carboplatin, cis-platin and ABC appear to be
active in advanced thyroid cancer. Useful palliation and
improved survival may be achieved in responders.
Thyroglobulin in the follow up of differentiated thyroid cancer
A.M. Cassoni & C.L. Harmer
The Royal Marsden Hospital, Sutton, Surrey, UK.
The results of a prospective study on the use of thyro-
globulin (Tg) in the follow up of patients with differentiated
thyroid cancer are presented. Those studied are a cohort of
patients seen for the first time or at follow up after effective
thyroid ablation, between June 1978 and December 1984. Of
178 patients, 170 had undergone total or subtotal
thyroidectomy and all had received ablative iodine. All were
examined regularly, had diagnostic 1311 scans 6-12 monthly
for at least 2 years and had Tg levels measured while taking
sufficient thyroid hormone to suppress TSH. Tg was assayed
by double radioimmunoassay. At initial assay 31 patients
had detectable Tg in the presence of proven disease. A
further 5 with detectable Tg subsequently developed disease
4 to 20 (median 12) months later. Two patients, while
initially disease free with undetectable Tg subsequently
developed elevated Tg 24, and 36 months before disease
became apparent. No patient has had disease detected by
routine scanning in the absence of an elevated Tg, but in 3
early patients with at least one undetectable Tg there was
evidence of recurrent or persistent disease. Of 136 patients
without disease at any stage, 29 have had detectable Tg on
at least one occasion. However, in all but 4 Tg has now been
undetectable for at least 2 years. Tg is an effective means of
detecting recurrent or persistent differentiated thyroid
carcinoma, without the need for stopping suppressive thyroid
hormone. In our view 1311 scanning should generally be
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Radiotherapy dose perturbations caused by amalgam dental
fillings
M.G. Samarasekara & F.R. Hudson
Physics Department, Mount Vernon Hospital, Northwood,
Middlesex, UK.
When patients receiving radiotherapy treatment to the head
and neck region have exposed amalgam dental fillings
significant dose perturbations may be caused. These will
result in small zones of high and low dosage and can result
in significant mucosal reactions.
Dose distributions have been measured for 5MV and for
Co-60 beams using film and ionisation chamber techniques,
to identify the magnitude and the range of the effects. The
results show the range to be of up to 3mm and the
magnitude of the perturbed dose to lie between 0.8 and 1.8
times the unperturbed dose.
The use of electrons in the treatment of intraoral cancer at
Mount Vernon Hospital
E.J. Maher, F.R. Hudson & M.G. Samerasekara
Department ofRadiotherapy, Mount Vernon Hospital,
Northwood, Middlesex HA6 2RN, UK.
Recent publications have suggested a role for electrons in the
treatment of intraoral malignancies. Standard electron
applicators can be relatively simply modified with an
extension adaptor with a slanted tip to allow apposition to
selected intraoral sites. The technique has been available at
Mount Vernon Hospital for the last 3 years.
Initially location devices were prepared by the dental
department, using acrylic material, but the effort involved,
bulk and lack of final flexibility were limiting factors. Latterly
we have used a simpler technique. A thermoplastic mould is
prepared with the patient holding a wide open mouth
position. A fixing tray is attached to this shell and the
intraoral applicator mounted, in its own separate support,
on this tray. Warm thermoplastic is used so the clinician can
angle the adaptor until satisfied with tumour cover. The
adaptor sets in place with no extra intraoral bulk restricting
access and a shell set removes the need for extreme delicacy
in positioning each day.
The value of the technique depends on careful patient
selection. Even with a large case load of intraoral malig-
nancy, only a few patients will be suitable. Over a 3 year
period, 20 were initially assessed as suitable and 12 treated,
both alone and in combination with external beam radiation.
Clinical uses and results will be compared with our
experience using intraoral moulds over the last 10 years.
Radiation therapy in the management of thymomas
A.W. Fyles & W.J. Simpson
The Princess Margaret Hospital, Toronto, Canada
The optimal management of patients suffering from
thymoma is controversial. A review of 69 patients seen at
The Princess Margaret Hospital between 1958 and 1980 was
undertaken to better define the role of radiation and
chemotherapy.
Twenty-one patients had non-invasive tumours, 46 had
invasive tumours and in two the degree of invasion could
not be determined. Myasthenia gravis was present in 19
patients.
Overall survival was 63% at 5 years; relapse-free survival
was 49% at 5 years. For patients with non-invasive tumours
the 5-year survival was 80% and for invasive tumours 54%.
Significant adverse prognostic factors included the pres-
ence of invasion, unresectable tumour and nodal metastases
at presentation. The presence of myasthenia gravis did not
influence survival.
Tumour recurrence in the mediastinum occurred in 20%
of patients with radiation including 50% of those with
unresectable tumour. Complete surgical resection, including
resection of pleural metastases if present, is the appropriate
initial management for patients with thymoma. Post-
operative radiation therapy is indicated for invasive tumours
and, combined with chemotherapy, is the primary form of
management for those that are unresectable.
A prospective randomised multicentre trial of adjuvant
methotrexate in T3 carcinoma of the bladder
A. Horwich
Co-operative Urological Cancer Group, Institute ofCancer
Research, Sutton, UK.
Four hundred patients were randomised to receive local
treatment (LT) alone, or LT plus methotrexate (LT+MTX)
for T3 bladder carcinoma. LT was irradiation (RT) in two
phases to 64Gy in 32 fractions in 6j weeks, except in some
centres where patients -65 years were treated with pelvic
RT to 44Gy followed by cystectomy. MTX (100mgm-2 i.v.
push with folimic acid rescue) was administered weekly for 3
weeks prior to RT, and following LT MTX dose 100mg
(total) q2 weeks for 3 months then q4 weeks for 9 months.
Of 360 evaluable patients with F/U more than 6 months
there was no significant difference in median survival
between 178 patients randomised to LT+MTX and 182 to
LT alone (23 vs. 17 months, P<0.1). The local recurrence
rate was 30% for 146 LT+MTX patients and 28% for 151
LT patients. Eighty-five (48%) of 178 LT+MTX patients
developed distant metastases compared to 86 (47%) of 182
Lt patients. There was no difference in the incidence of early
side effects of treatment. It was concluded that adjuvant
methotrexate was not effective in the context of this study.
The use of serum prostate specific antigen (PSA) estimation in
monitoring hormonal therapy for prostatic carcinoma
D.A. Gillatt, M. Ferro, I. Barnes & P.J.B. Smith
Bristol Royal Infirmary, Bristol, UK.
It is widely accepted that advanced prostatic carcinoma will
respond to a reduction of circulating testosterone levels in
more than 80% of cases. Various methods including bilateral
orchidectomy, gonadotrophin analogues and antiandrogens
are in use in our unit. Traditionally treatment response is
monitored clinically and by measurement of prostatic acid
phosphatase (PAP). Acid phosphatase is, however, raised
prior to treatment in only 60% of cases and will be of little
use on many occasions.
Prostate specific antigen is produced in the cytoplasm of
prostatic cells. It can be measured in serum by an immuno-
radiometric assay. It is raised above the usually accepted
upper limit of normal of lOngml-1 in 95% of men with
metastatic prostatic cancer. Forty-two patients are being
followed up with regular PSA measurement following
hormonal manipulation for advanced prostatic cancer. Four
patients showed no clinical response, in each case PSA
continued to rise. The remaining 38 patients showed good
clinical response with a fall in serum PSA levels. It is of
interest that the rate of fall varied from rapidly to normal
within 1 to 3 months to a more gradual fall over 6 months
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Serum prostatic specific antigen measurement provides a
more sensitive monitor of prostatic carcinoma than either
acid or alkaline phosphatase. PSA should be the main
tumour marker for prostatic cancer.
Platinum induced renal damage
C.R. Hamilton & A. Horwich
Royal Marsden Hospital, Sutton, Surrey, UK.
Seventeen patients presenting to the Testicular Tumour Unit
of the RMH with malignant teratoma were studied to assess
the late renal toxicity of 'BEP' chemotherapy (4-6 courses).
All had normal GFR's as assessed by EDTA renal
clearance, and no evidence of obstructive uropathy or past
medical history of renal disease. GFR was measured before
any chemotherapy and before subsequent courses. It was
also assessed in these patients who were rendered disease free
8-57 months (median 31 months) after cessation of all
chemotherapy (post-treatment GFR). The mean GFR fell
from 132mlmin-' (95% confidence limit 123-141) to
107mlmin- (95% confidence limit 100-114) whilst on
treatment. The post-treatment GFR mean was 103mlmin-1.
Of the 17 patients, the post-treatment GFR improved by
over 10% in 5 patients and continued to fall by more than
10% in 5 patients, the most notable being from a pre-
treatment GFR of 157mlmin-' to 116mlmin-' on
treatment, to a post-treatment value of 75mlmin- two
years after cessation of chemotherapy.
Comparative sensitivities of human bladder and testicular germ
cell tumours to chemotherapeutic drugs and gamma-radiation
in vitro
J.R.W. Masters, M.C. Walker, C.N. Parris, A.R. Lehmann,
M.L.H. Greene & C.F. Arlett
Institute of Urology, London and MRC Cell Mutation Unit,
University ofSussex, Brighton, UK.
Adriamycin, cis-platin and gamma-radiation sensitivities in
vitro of continuous cell lines derived from 5 human non-
seminomatous testicular germ cell tumours and 5 human
transitional cell carcinomas of the bladder were compared.
The range of adriamycin concentrations reducing clonogenic
cell survival by 70% following continuous exposure for the
testicular cell lines was 0.8-7.2ngml-1, compared with 3.6-
18.6ngml-1 for the bladder cell lines, and the corresponding
figures for cis-platin were 19-161 and 112-431 ngml-1. Cis-
platin binding to DNA following exposure to an equimolar
concentration was identical in a bladder and a testicular line
with a two-fold difference in sensitivity. There was no
correlation between population doubling time and drug
sensitivity. Extrapolating from the gamma-radiation survival
curves, Do values for the bladder lines ranged from 1.6-
2.1 Gy, compared with 1.2-1.5Gy for the testicular lines.
DNA synthesis following gamma-radiation was not inhibited
in two testicular cell lines to the same extent as that in two
bladder lines.
It is concluded that testicular germ cell tumours retain
their characteristic sensitivity to cytotoxic agents in vitro.
Consequently, drug sensitivity probably is an inherent
feature of these tumour cells, and not dependent on humoral
factors such as blood supply or immunogenicity. Our
preliminary data suggest that testicular tumour cells may
have a relatively low capacity to repair DNA following
exposure to cytotoxic agents.
Regression of carcinoma of bladder after radical radiotherapy
E.M. Bessell
The Hogarth Centre ofRadiotherapy and Oncology,
Nottingham, UK.
A study of the regression of carcinoma of the bladder after
radical radiotherapy was undertaken to determine whether
there was any correlation between the rate of regression and
the time to recurrence. This information would be useful in
predicting which patients might need salvage cystectomy.
Twenty patients with carcinoma of the bladder, treated
with radical radiotherapy have been studied so far. The
regression of primary bladder carcinoma was measured
during and after radical radiotherapy. In 12 patients the
regression was determined by transabdominal ultrasound
alone and in 8 patients by ultrasound and by computed
tomography.
The regression of transitional-cell carcinoma of the
bladder after radiotherapy is much slower than for
squamous cell carcinoma of the head and neck or for
carcinoma of the breast. The range of volume-halving time
was 7-105 days (median 39 days). Considerable calcification
occurred during the regression of some of these tumours.
Cis-platinum before radical radiotherapy in transitional cell
carcinoma of the bladder: Interim report of the West Midlands
CRC trial
I.G. Conn
Queen Elizabeth Hospital, Birminghamfor the West Midlands
Urological Research Group, UK.
A prospective randomised trial is in progress in the West
Midlands region to assess the value of three courses of cis-
platinum (cis-diaminodichloroplatinum) 100mgm-2 at 3
weekly intervals before radiotherapy (64Gy/30 fractions)
compared with radical radiotherapy alone in invasive
transitional cell carcinoma of the bladder. From July 1984 to
January 1987, 108 patients have been entered into the trial
from 9 centres in the region. Fifty-seven patients have been
randomised to receive chemotherapy of whom 39 have
completed three courses at full dosage. Reasons for dose
reduction or cessation have been low creatinine clearance in
15 and myelosuppression in 6.
The initial response to chemotherapy has been assessed by
CAT scan tumour volume measurement before and after 3
courses of cis-platinum. Thirty-nine patients have pre- and
post-chemotherapy scans of whom 30 have evaluable disease
(T3 or T4). Eighteen (60%) have shown a greater than 50%
reduction in tumour volume following chemotherapy.
Of 85 patients evaluable, 75 (88%) have completed a full
course of radical radiotherapy. No increased toxocity in the
chemotherapy group has been noted.
It is hoped that the initial response to cis-platinum will be
reflected in improved local control and increased survival.
Ultrasound guided transperineal 1125 seed implantation for
prostatic carcinoma
J.M. Rodriguez', M. Halliwellt, H. Appleby', H. Eckert',
E.C. Whippl, A. Fellows2, K. Durrant2, R. Belton2,
C. Keen3, B. Peeling3, A. Tyler3, S. Carter4,
N. O'Donoghue4 & J. Tobias4
'Bristol, 2Oxford, 3Newport and 4London, UK.
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developed as an alternative to external beam radiotherapy
for early prostatic carcinoma. Initial experience is reported
from four centres: Bristol Radiotherapy and Oncology
Centre, St Woolos Hospital Newport, St Peter's Hospital in
association with University College Hospital London,
Churchill Hospital, Oxford.
Thorough preoperative staging is performed and
meticulous preliminary planning is required to construct a 3
dimensional model of the prostate and to calculate the
number of seeds necessary to deliver a matched peripheral
dose of 160Gy. Implantation is carried out under general
anaesthesia using a Bruel and Kjaer 1846 transrectal ultra-
sound scanner with a special grid attachment which allows
precise spatial distribution of seeds within the gland.
Thirty-seven patients with early disease (TO, T1,T2,No,MO)
have been treated; 35 of these were well differentiated
tumours. There has been no operative mortality and very
little immediate morbidity and late complications are rare,
but include impotence (2), incontinence (1) and perineal pain
(1). Despite the high radiation dose to the prostate itself, the
rectal dose is minimal in contrast to external beam therapy.
An early response is commonly seen as a diminution of
prostate volume. Follow up is from 4 months to 2 years.
Two patients with poorly differentiated tumours have
undergone disease progression.
Time in hospital is 3 days contrasting with 5 to 6 weeks
for external beam therapy. Transperineal placement of 1125
seeds is a simple effective treatment for early prostatic
carcinoma.
treated between 1958 and 1984 in order to define the natural
history of the second tumour. There was a history of
maldescent in 28% of evaluable patients, infertility in 22%,
and both maldescent and infertility in 21%. The distribution
of histology of the first tumour (seminoma in 17, teratoma
in 11, combined tumours 3) was not significantly different
from the distribution in the second tumour (seminoma 15,
teratoma 8, combined 7). Additionally, there were 4 patients
who presented with synchromous tumours and 2 of these
had different histologies in the 2 tumours.
Twenty-nine patients had no treatment to the contralateral
testis following their first orchidectomy (abdominal node
irradiation in 23 patients, surveillance in 5 patients and node
dissection in 1 patient). Two patients were treated with
chemotherapy for their first testicular tumour. One patient
received four courses of bleomycin, etoposide and cis-
platinum which he completed 4y years before the
presentation of his second tumour. He is disease-free one
year after his second orchidectomy. The other received 6
courses of vinblastine and bleomycin which he completed 9
months before the presentation of his second tumour. He
died with widely disseminated disease 14 months after his
second orchidectomy despite further chemotherapy.
Testicular biopsy studies suggest that tumours are unlikely to
arise in the absence of carcinoma in situ and this study
would suggest that chemotherapy does not prevent
development of all testicular tumours.
Multiple fractions per day - pelvic irradiation
M. Quigley, M. Brada, J. Bradbeer & A. Horwich
Royal Marsden Hospital and Institute ofCancer Research,
Sutton, Surrey, UK.
With the intention of defining early tolerance of accelerated
fractionation in pelvic irradiation a schedule was developed
employing multiple fractions per day and gradually
decreasing overall treatment time. We report acute reactions
in 34 patients treated for palliation of advanced inoperable
pelvic malignancies (24 colorectal tumours, 9
bladder/prostatic tumours and one sarcoma). A total dose of
48.6Gy was given in 3 blocks consisting of 1.8Gy fractions
given 3 times per day for 3 days with at least 3' hours
between fractions. The overall treatment time (OTT) was
varied by reducing the interval between the 3 day blocks.
Twenty-seven patients had schedule A (OTT=31 days), and
7 patients schedule B (OTT=24 days). Acute toxicity was
scored using WHO grades. The major acute toxicity was
gastro-intestinal (GI); 56% of patients in schedule A had GI
toxicity (15% Grade 1, 22% Grade 2, 18% Grade 3, and
0% Grade 4), compared to 72% of patients in schedule B
(29% Grade 1, 14% Grade 2, 29% Grade 3 and 0% Grade
4). Only 3 patients had significant skin toxicity (WHO Grade
3) and all had received schedule B. Nine patients had genito-
urinary toxicity, which was Grade 1 or 2 in all cases. Both
schedules were well tolerated. Patients treated with schedule
B had more acute toxicity, but this did not cause delay in
treatment or significant distress.
Bilateral testicular tumours
M. Mason & A. Horwich
Radiotherapy Unit, The Royal Marsden Hospital, Sutton,
Surrey, UK.
A retrospective analysis was performed of 35 patients with
bilateral testicular germ-cell tumours whose first tumour was
Modification in cardiac function in rats after single doses of
anthracyclines
T.K. Yeung, R.H. Simmonds & J.W. Hopewell
Research Institute, Churchill Hospital, Oxford OX3 7LJ, UK.
Modification to the cardiac output in Sprague Dawley rats
was assessed following the intravenous administration of
single doses of epirubicin (2-10mgkg-1). Cardiac function
was measured using an isotope dilution technique at 4-
weekly intervals for up to 20 weeks. After a sharp initial
decline in cardiac function in drug treated animals (phase I),
values remained persistently depressed (phase II) indicating
the irreversible nature of anthracycline-associated cardiac
lesions. The duration of phase I varied from 4 to 12 weeks
depending on dose. In phase II cardiac output values were
relatively stable for most animals and deterioration in heart
function was usually only in those rats which had shown a
>40% reduction in cardiac function in phase I. There were
no statistically significant differences between the mean heart
rate measured in drug treated and age-matched control
animals. This suggested that the reduction in cardiac
function was due to the loss of contractile elements in the
cardiac muscle. The 50% incidence dose (ED50) for a >30%
or a >50% reduction of cardiac output, 12 weeks after drug
treatment, was 3.34+0.4mgkg-1 and 4.93 +0.43mgkg-'
respectively.
After the administration of single doses of adriamycin, the
modification in cardiac function followed the same time
course to that after epirubicin. However, adriamycin showed
a greater acute effect and cardiotoxicity. Adriamycin was
found to be twice as cardiotoxic as epirubicin and this was
independent of the drug dose and hence the level of damage
in the heart.878 SECOND SCIENTIFIC MEETING OF THE BRITISH ONCOLOGICAL ASSOCIATION
Management of radiation enteritis - An algorithmic guide
P.L. Zentler-Munro & E.M. Bessell
St. George's Hospital Medical School, London; and Hogarth
Centre, Nottingham, UK.
The management of diarrhoea and steatorrhoea due to
radiation enteritis can prove troublesome. Several patho-
physiological abnormalities can be involved, each requiring
specific therapy. Choosing the treatment most likely to
succeed in each case therefore depends on identifying which
mechanism is involved. Gastroenterologists have recently
developed several non-invasive diagnostic techniques which
can be used to pinpoint the precise cause in each case simply
and rapidly. Some of these tests - to identify di- and mono-
saccharide malabsorption, bile acid deconjugation, bile acid
malabsorption, gut hurry and mucosal inflammation - may
not be familiar to radiotherapists.
An algorithm has therefore been devised in which each of
the tests is arranged so as to arrive at a diagnosis with as
few procedures as possible, but it has yet to be formally
tested.
The effect of WR-2721 and antacid therapy on gastric
distension caused by a platinum (i.v.) cytotoxic drug
B. Jones1 & M.G. Stone2
'Radiotherapy Department, London Hospital; and 2Richard
Dimbleby Department, St. Thomas Hospital, UK.
Many clinical studies have shown that the thiophosphate
radioprotective compound WR-2721 has emetic side effects
and does not protect against the emetic effects of cytotoxic
drugs and radiation. This may be due to the known
degradation of WR-2721, forming toxic metabolites, at low
pH values as found in gastric juice. The effect of
neutralisation of stomach pH was tested in an animal model.
C3H mice were given WR-2721 (400kg-1 i.p.) both with
and without antacid treatment (oral sodium bicarbonate and
cimetidine) 1 h before and 24h following the i.p.
administration of the platinum (i.v.) compound CHIP which
causes marked gastric (volume) distension at doses between
5mgkg-1 and 90mgkg-1 (LD 50/30=65mgkg-1). WR-
2721 caused increased distension at lower CHIP doses (5-
20mgkg-1). At higher CHIP doses (30-90mgkg-1) the
following average reductions in gastric distension were seen:
WR-2721 alone -27%; WR-2721 +antacids -35%;
antacids alone -33%.
Antacid treatment alone was as effective as WR-2721 at
high CHIP doses but did not cause enhanced distension at
lower doses. A reduced food and water intake seen with
WR-2721 and antacids did not account for the low dose
results but this mechanism may be operative at higher doses
although a direct effect on stomach pH in vivo has not been
excluded. A clinical trial utilising antacid drugs in situations
involving a high risk of emesis is suggested.
Late normal tissue damage following intra-arterial adriamycin
plus radiotherapy and conservation surgery for soft tissue
sarcomas
M. Mason, C. Harmer & G. Westbury
Sarcoma Unit, Royal Marsden Hospital, London, UK.
The use of intra-arterial adriamycin as an adjunct to radio-
therapy and limb conserving surgery has previously been
described in an attempt to improve local control rates
without amputation in the primary treatment of soft tissue
sarcoma (STS). The late normal tissue damage that was
described following such an approach raised concern about
its toxicity, and prompted a pilot study, which is presented
here, in which late normal tissue damage was specifically
assessed. Ten patients with STS were treated by this tri-
modality approach using conventionally fractionated radio-
therapy; their late normal tissue damage was compared with
that in 10 patients recently treated by radiotherapy and
conservation surgery without adriamycin. No significant
difference in late morbidity was observed between the two
groups. This approach appears safe provided conventional
fractionation is employed. The late normal tissue damage
seen in previous series might be accounted for by the
unconventional radiotherapy fractionation employed. It
remains to be proven that the addition of intra-arterial
adriamycin to surgery and radiotherapy confers any benefit
in terms oflocal control or survival.
A randomized prospective observer blind trial of E45 cream in
the early skin reaction following post-mastectomy chest wall
radiotherapy
M.H. Robinson
Royal Marsden Hospital, London, UK.
Management of the early skin reaction to orthovoltage
radiotherapy is controversial. There are proponents and
opponents of treatment with medicated and non-medicated
skin creams. Use of a new formulation of E45 cream was
therefore studied in patients who received post-mastectomy
radiotherapy to the chest wall and/or the axilla and supra-
clavicular region (a mid-plane dose of 38Gy in 10 fractions
over 28 days given 3 times a week).
Patients were randomised to apply E45 cream twice daily
for 28 days or not at all after radiotherapy (day 0). The
doctor assessed the skin reaction with 5 point scales for
severity of reaction, redness, dryness, itchiness and soreness
on days 0, 14 and 28. Patients kept daily records. At day 14,
the physician determined whether patients needed treatment
for the skin reaction. If so, this was dispensed. The group
using the cream previously continued to do so.
Forty-two patients entered. Groups were comparable in
the development of the skin reaction. Significant differences
(P<0.01) were found in favour or E45 cream for skin
dryness in patients with constant and changed therapy. Skin
soreness at day 28 was less (P<0.02) in untreated patients
assigned to use E45 cream from day 14. Patients therefore
benefit from E45 cream application as therapy for the acute
skin reaction to radiotherapy.
Endoscopic laser treatment for tracheobronchial tumours
P.J.M. George1, C.P.O. Garrett2 and M.R. Hetzel
Departments of 1Thoracic Medicine and 2Anaesthetics,
University College Hospital, London WCJ, UK.
Although endoscopic laser treatment is an established
palliative treatment in patients with advanced lung cancer,
little is known of its effects on lung function and quality of
life. We have treated 105 patients with a neodymium YAG
laser under general anaesthesia. The indications for
treatment were either breathlessness, due to partial or
complete airway obstruction by intraluminal tumour (95
patients), or haemoptysis (10 patients). Assessments of
breathlessness, wellbeing, performance status and lung
function were made before and after treatment.
In patients with partially obstructed airways (n=79), an
overall symptomatic improvement was noted in 59 (75%),
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51 (65%). Patients with tracheal and main carinal tumours
(n=49) reported the most impressive symptomatic gains and
exhibited the most marked increases in peak flow (mean rise
of 57%; P<0.001) and FEV1. In patients with partial
obstruction of more peripheral airways (mainstem and
lobar-bronchi; n=30), symptom scores and lung function also
improved significantly (P<0.01). In patients with complete
endobronchial obstruction (n= 16), treatment was successful
in 9 (56%); re-expansion was associated with improved
symptom scores and increases in FVC, the best results being
seen in patients with main bronchial obstruction (P<0.05).
Haemoptysis was completely abolished in 8 patients (80%);
the period of relief ranged from 3 weeks to 4 months.
We conclude that endoscopic laser treatment provides
significant relief from haemoptysis and breathlessness in
selected patients, and that the response in patients with
breathlessness varies according to the level of obstruction.
Management of severe malignant pelvic pain by intrathecal
opiates, administered by an implanted intrathecal catheter and
subcutaneous reservoir
M. Powell
Department ofNeurosurgery, The Middlesex Hospital,
London WI, UK.
Intrathecal opiates have been administered to 6 patients with
severe pain from disseminated malignant disease resistant to
oral and intramuscular analgesia. The pain was mainly pelvic
in origin.
The system consists of standard components of a lumbo-
peritoneal shunt (approximately £280). Implanted under
general anaesthetic a 4FG catheter is introduced by a Tuohy
needle into the lumbar sac and connected to a 3.5ml
subcutaneous reservoir over the ribs, allowing percutaneous
intrathecal injections. In 5 cases the patient could stop all
alternative means of opiate administration, to be replaced by
either OM or bd diamorphine 5-15mg in various dilutions
of saline (usually 10mg in 7ml). Three patients returned
home, diamorphine being given by GP, district nurse and
spouse. Two (with colostomies) required the systems removal
for skin commensal meningitis at 6 and 8 weeks. The third
patient's reservoir was replaced because of multiple puncture
leakage at 10 weeks. The remaining patients died relatively
pain-free in hospital.
A similar system was placed epidurally following the
removal of the first for meningitis. It was not successful. An
alternative subcutaneous system (Cordis Secor TM cost
£490) is being evaluated at present. It has a measured dose
pump, patient administered on demand from a reservoir
holding approximately 1 month's supply of morphine.
In conclusion, a simple, cheap and effective system for
pain control is presented, best for short-term use and contra-
indicated in colostomy patients in community care. A better
but more expensive long-term system is under evaluation.
The role of computed tomography (CT) in selecting patients
for hindquarter amputation (HQA)
R.M. Warkins & J.M. Thomas
Westminster Hospital, London, UK.
The suitability of patients with sarcomas of the thigh,
buttock or pelvis for HQA is usually determined by clinical
examination. Our aim was to evaluate the role of CT in
assessing their operability.
Ten patients were referred for HQA. Patients were
considered unsuitable for HQA if on surface examination
malignant disease extended into the perineum, across the
sacro-iliac joint or above the inguinal ligament. Buttock
tumours palpable on pelvic examination were also considered
inoperable. Tumours were considered inoperable if CT
showed buttock disease extending through the greater sciatic
notch, the psoas muscle was involved above the inguinal
ligament, the disease crossed the sacro-iliac joint or the
perineal structures were involved.
Five patients thought suitable for HQA on clinical assess-
ment had no excluding features on CT. One refused surgery;
4 undergoing HQA had no malignant disease at the resection
margins. In a further patient, considered suitable for ampu-
tation, CT suggested that wide excision of the tumour with
limb-preservation was feasible. After clinical examination 4
patients were considered unsuitable for HQA; CT confirmed
inoperability in each case.
The results of clinical assessment are usually confirmed by
CT which provides an objective means of selecting patients
for HQA. CT may also identify those patients suitable for
limb-preservation.
Lymphokines in malignant melanoma
D.C. Dumonde1, M.S. Pulley1, J.M. Edwards2 and
A.R. Timothy3
Departments of lImmunology and 3Radiotherapy and
2Surgical Unit, St. Thomas' Hospital, London, UK.
Lymphokines are non-antibody proteins generated by
lymphocyte activation; current evidence implicates lympho-
kines in effecting both specific and non-specific immunity.
The rationale for administering lymphokines in malignant
melanoma is to assist host defence mechanisms against
tumour spread and to help maintain the integrity of the
immune system. In this paper we review current approaches
to the therapeutic investigation of lymphokines in malignant
melanoma.
Rosenberg and colleagues have reported that i.v. adminis-
tration of high dose interleukin-2 (IL-2) both alone and in
combination with autologous lymphocytes activated ex vivo
with IL-2 (LAK cells) has resulted in regression of
melanoma. In our preliminary work we have used buffy-coat
interleukin (BC-IL), containing several lymphokine activities
including IL-2, which has so far been well tolerated.
Endolymphatic administration of lymphokines and LAK
cells may be particularly appropriate in melanoma which
spreads primarily by lymphatic pathways. We have
demonstrated clinical, radiological and histological evidence
of lymph node activation following administration of BC-IL
by this route.
Our experience and that of other investigators suggests
that the administration of lymphokines may be of value in
malignant melanoma. Protocols need to be designed to
explore methods of administration in patients with disease of
different stages and the administration of lymphokines as an
adjunct to other forms of treatment. The monitoring of
white-cell function in these patients may yield important
information in the design of these protocols.
Hyperthermia sensitivity of human melanoma and
neuroblastoma cells grown as multicellular spheroids
R.D. Jones, I. Berry, R. Hamlet & T.E. Wheldon
Glasgow Institute ofRadiotherapeutics and Oncology, UK.
Malignant melanoma and neuroblastoma are cancer types
which differ markedly in their clinical radiosensitivity.
Interest exists in possible treatment of radioresistant tumours
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one therapeutic procedure involves combined use of hyper-
thermia with melphalan via the technique of isolated limb
perfusion. Experimental studies of heat sensitivity of
melanoma and other tumour types may be of clinical
relevance. Multicellular spheroids derived from melanoma
and from neuroblastoma were subjected to various regimes
of heat treatment in the temperature range 39-45°C.
Spheroid responses were quantified by analysis of regrowth
curves to yield estimated cell survival data. Arrhenius plots
were constructed and activation energies calculated. These
studies may be useful in relating radiosensitivity to heat
sensitivity and in the design of clinical studies in which
hyperthermia is a therapeutic component.
The prospects for radioimmunotherapy of occult metastases
using antibody-targeted 131I
T.E. Wheldon, J.A. O'Donoghue, T.E. Hilditch & A. Barrett
Glasgow Institute ofRadiotherapeutics and Oncology, UK.
Radioimmunotherapy entails selective irradiation of tumour
cells by delivery of radionuclides conjugated to antibodies.
Mathematical models studies show that radioimmunotherapy
using 1311 is not yet capable of delivering radical doses to
occult metastases. This is because the limited specificity of
available antibodies results in high doses to normal tissues,
especially bone marrow. The analysis suggests, however, that
radioimmunotherapy followed by bone marrow rescue
should be an effective treatment. Logistic considerations
imply that the optimal strategy might be a combination of
radioimmunotherapy, external-beam TBI and marrow
rescue. This combination strategy presently seems the most
promising appraoch to use of radioimmunotherapy as
treatment for occult metastases.
Manipulation of tumour oxygenation to increase the potency
of bioreductive radiosensitizers
G.E. Adams & I.J. Stratford
MRC Radiobiology Unit, Chilton, Didcot, UK.
The vasocactive drug hydralazine can cause substantial
changes in blood flow to murine tumours. One result of
these changes in the induction of close to 100% hypoxia in
subcutaneous tumours, which lasts for nearly 2h following
an i.v. injection of 5mgkg-1. Induction of tumour hypoxia
could be therapeutically beneficial, particularly when used
with radiation and the nitroimidazole radiosensitizers. This is
demonstrated with results obtained using the KHT tumour
in vivo when the following treatment schedule is employed:
Sensitizer-.60min-.X-rays-+1 min-÷hydralazine.
Such a strategy will first exploit the radiosensitizing
properties of the nitroimidazole, then after irradiation
administration of hydralazine will induce tumour hypoxia
and allow expression of the differential toxicity towards
hypoxic cells known to occur with agents such as RSU 1069
and misonidazole.
This approach results in a substantial increase in the
apparent efficiency of misonidazole and RSU 1069 as radio-
sensitizers. For example, the enhancement of tumour cell
killing achieved by 100mgkg-1 misonidazole when used in
combination with hydralazine is equivalent to that obtained
by 1000mgkg -1 misonidazole alone.
Trials data collection by portable microcomputer
S.N. Larson
CRC Clinical Trials Unit, Birmingham, UK.
Data collection for large trials usually involves three stages:
(1) recording data in the clinical notes; (2) filling in study
forms; (3) transferring data to the unit's computer system for
analysis.
We are streamlining this process using an easily portable
microcomputer and software developed in-house, allowing
direct data collection in the clinic and transfer to our main
unit computer system for detailed analysis. We use an IBM-
compatible Datavue 25 portable microcomputer with 768
kilobytes of random access memory and twin built-in 3.5
inch disc drives, each with 720 kilobytes of storage. The
software is written in Psion Archive, an advanced
programmable database language. it is designed to be menu
driven, suitable for users with no computer expertise. Data
collected at the clinic are stored as a database file, with one
record of 139 fields per patient. String fields are used with
each data item for a particular visit concatenated to the
existing string for that field. Routines have been developed
which allow data to be 'sliced' out of this string
appropriately. As the trials in question were under way
before the computer was acquired, a facility is provided to
collect data retrospectively from clinical notes.
Further software allows data to be presented as a
standardised printout of all data for a patient, or data for
one visit. This facilitates subsequent entry of data into the
unit VAX minicomputer. The software already developed
involves - 70 kilobytes of programming. We are now
developing protocols for direct file transfer from the Datavue
to the VAX via its integral serial interface.